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Preamble and Transition to ACC/AHA
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC)
and the American Heart Association (AHA) are to prevent
cardiovascular diseases; improve the management of people
who have these diseases through professional education
and research; and develop guidelines, standards, and pol-
icies that promote optimal patient care and cardiovascular
health. Toward these objectives, the ACC and AHA have
collaborated with the National Heart, Lung, and Blood
Institute (NHLBI) and stakeholder and professional or-
ganizations to develop clinical practice guidelines for
assessment of cardiovascular risk, lifestyle modiﬁcations to
reduce cardiovascular risk, management of blood choles-
terol in adults, and management of overweight and obesity
in adults.
In 2008, the NHLBI initiated these guidelines by
sponsoring rigorous systematic evidence reviews for each
topic by expert panels convened to develop critical ques-
tions (CQs), interpret the evidence, and craft recommen-
dations. In response to the 2011 report from the Institute
of Medicine on the development of trustworthy clinical
guidelines (1), the NHLBI Advisory Council recom-
mended that the NHLBI focus speciﬁcally on reviewing
the highest-quality evidence and partner with other orga-
nizations to develop recommendations (2,3). Accordingly,
in June 2013 the NHLBI initiated collaboration with the
ACC and AHA to work with other organizations to
complete and publish the 4 guidelines noted above and
make them available to the widest possible constituency.
Recognizing that the Expert Panels/Work Groups did not
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methodology), the ACC, AHA, and collaborating societies
plan to begin updating these guidelines starting in 2014.
The joint ACC/AHA Task Force on Practice Guide-
lines (Task Force) appointed a subcommittee to shepherd
this transition, communicate the rationale and expectations
to the writing panels and partnering organizations, and
expeditiously publish the documents. The ACC/AHA and
partner organizations recruited a limited number of expert
reviewers for ﬁduciary examination of content, recognizing
that each document had undergone extensive peer review
by representatives of the NHLBI Advisory Council, key
federal agencies, and scientiﬁc experts. Each writing panel
responded to comments from these reviewers. Clariﬁca-
tions were incorporated where appropriate, but there were
no substantive changes because the bulk of the content was
undisputed.
Although the Task Force led the ﬁnal development of
these prevention guidelines, they differ from other ACC/
AHA guidelines. First, as opposed to an extensive com-
pendium of clinical information, these documents are
signiﬁcantly more limited in scope and focus on selected
CQs on each topic, based on the highest-quality evidence
available. Recommendations were derived from randomized
trials, meta-analyses, and observational studies evaluated for
quality and were not formulated when sufﬁcient evidence
was not available. Second, the text accompanying each
recommendation is succinct, summarizing the evidence for
each question. The Full Panel/Work Group Reports include
more detailed information about the evidence statements
that serve as the basis for recommendations. Third, the
format of the recommendations differs from other ACC/
AHA guidelines. Each recommendation has been mapped
from the NHLBI grading format to the ACC/AHA Clas-
siﬁcation of Recommendation/Level of Evidence (COR/
LOE) construct (Table 1) and is expressed in both formats.
Because of the inherent differences in grading systems and
the clinical questions driving the recommendations, align-
ment between the NHLBI and ACC/AHA formats is in
some cases imperfect. Explanations of these variations are
noted in the recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by
the writing panels to manage relationships of authors with
industry and other entities (RWI) are outlined in the
methods section of each panel report. These policies were
in effect when this effort began in 2008 and throughout
the writing process and voting on recommendations, until
the process was transferred to ACC/AHA in 2013. In the
interest of transparency, the ACC/AHA requested that
panel authors resubmit RWI disclosures as of July 2013.
Relationships relevant to this guideline are disclosed in
Appendix 1. None of the ACC/AHA expert reviewers had
relevant RWI (Appendix 2). See Appendix 3 for a list of
abbreviations used in the guideline.
Systematic evidence reports and accompanying sum-
mary tables were developed by the expert panels andNHLBI. The guideline was reviewed by the ACC/
AHA Task Force and approved by the ACC Board
of Trustees, and the AHA Science Advisory and Coor-
dinating Committee. In addition, ACC/AHA sought
endorsement from other stakeholders, including profes-
sional organizations. It is the hope of the writing panels,
stakeholders, professional organizations, NHLBI, and
Task Force that the guidelines will garner the widest
possible readership for the beneﬁt of patients, providers,
and the public health.
These guidelines are meant to deﬁne practices that
meet the needs of patients in most circumstances and
are not a replacement for clinical judgment. The ulti-
mate decision about care of a particular patient must be
made by the healthcare provider and patient in light of
the circumstances presented by that patient. As a result,
situations might arise in which deviations from these
guidelines may be appropriate. These considerations
notwithstanding, in caring for most patients, clinicians
can employ the recommendations conﬁdently to reduce
the risks of atherosclerotic cardiovascular disease
(ASCVD) events.
See Tables 1a and 1b for an explanation of the NHLBI
recommendation grading methodology.
1. Introduction
1.1. Organization of the Panel
The Blood Cholesterol Expert Panel (Expert Panel) was
originally convened as the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel IV) appointed by
the NHLBI. The Expert Panel was composed of 13
members and 3 ex-ofﬁcio members, which included pri-
mary care physicians, cardiologists, endocrinologists, and
experts in clinical lipidology, clinical trials, cardiovascular
epidemiology and nutrition, and guideline development.
The Expert Panel chair asked all panel members to disclose
any conﬂict-of-interest information to the full panel in
advance of the deliberations; members with conﬂicts were
asked to recuse themselves from voting on any aspect
of the guideline for which a conﬂict might exist. All 16
members of the NHLBI Adult Treatment Panel IV Panel
transitioned to the ACC/AHA guideline Expert Panel.
Independent contractors performed the systematic review
with the assistance of the Expert Panel and provided
methodological guidance to the Expert Panel.
1.2. Document Review and Approval
A formal peer review process was initially completed under
the auspices of the NHLBI and included 23 expert re-
viewers and representatives of federal agencies. This doc-
ument was also reviewed by 4 expert reviewers nominated
by the ACC and the AHA when the management of the
guideline transitioned to the ACC/AHA. The ACC and
Table 1. Applying Classiﬁcation of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.
Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889–934
2892AHA reviewers’ RWI information is published in this
document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and AHA and endorsed by
the American Academy of Physician Assistants, American
Association of Cardiovascular and Pulmonary Rehabilita-
tion, American Pharmacists Association, American Society
for Preventive Cardiology, Association of Black Cardiol-
ogists, Preventive Cardiovascular Nurses Association, and
WomenHeart: The National Coalition for Women with
Heart Disease.
1.3. Scope of Guideline
This guideline is based on the Full Panel Report, which
is provided as an online-only data supplement to theguideline. The Full Panel Report contains background and
additional material related to content, methodology, evi-
dence synthesis, rationale, and references and is supported
by the NHLBI Systematic Evidence Review, which can be
found at http://www.nhlbi.nih.gov/guidelines/cholesterol/ser/.
Table 2 provides an overview to facilitate understanding
what is new in the present guideline.
The Expert Panel was charged with using data from
randomized controlled trials (RCTs) and systematic reviews
and meta-analyses of RCTs to update the clinical practice
recommendations for the treatment of blood cholesterol
levels to reduce ASCVD risk. For this guideline, ASCVD
includes coronary heart disease (CHD), stroke, and pe-
ripheral arterial disease, all of presumed atherosclerotic
origin. These recommendations are intended to provide a
Table 1a. NHLBI Grading of the Strength of
Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net beneﬁty
is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net beneﬁt is
moderate to substantial, or there is high certainty that the net
beneﬁt is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that there is a
small net beneﬁt.
D Recommendation against
There is at least moderate certainty based on evidence that
there is no net beneﬁt or that risks/harms outweigh beneﬁts.
E Expert opinion (“There is insufﬁcient evidence or evidence is
unclear or conﬂicting, but this is what the Work Group
recommends.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence,
unclear evidence, or conﬂicting evidence, but the Work Group
thought it was important to provide clinical guidance and
make a recommendation. Further research is recommended
in this area.
N No recommendation for or against (“There is insufﬁcient evidence or
evidence is unclear or conﬂicting.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence, unclear
evidence, or conﬂicting evidence, and the Work Group thought
no recommendation should be made. Further research is
recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned with the quality
of the evidence; however, under some circumstances, there may be valid reasons for making
recommendations that are not closely aligned with the quality of the evidence (e.g., strong
recommendation when the evidence quality is moderate, such as smoking cessation to reduce
cardiovascular disease risk or ordering an ECG as part of the initial diagnostic work-up for a
patient presenting with possible MI). Those situations should be limited and the rationale
explained clearly by the Work Group.
yNet beneﬁt is deﬁned as beneﬁts minus risks/harms of the service/intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, National Heart, Lung,
and Blood Institute.
Table 1b. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
 Well-designed, well-executedy RCT that adequately
represent populations to which the results are applied
and directly assess effects on health outcomes.
 Meta-analyses of such studies.
Highly certain about the estimate of effect. Further
research is unlikely to change our conﬁdence in the
estimate of effect.
High
 RCT with minor limitationsz affecting conﬁdence in,
or applicability of, the results.
 Well-designed, well-executed nonrandomized controlled
studiesx and well-designed, well-executed observational
studiesk.
 Meta-analyses of such studies.
Moderately certain about the estimate of effect. Further
research may have an impact on our conﬁdence in the
estimate of effect and may change the estimate.
Moderate
 RCT with major limitations.
 Nonrandomized controlled studies and observational
studies with major limitations affecting conﬁdence in,
or applicability of, the results.
 Uncontrolled clinical observations without an appropriate
comparison group (e.g., case series, case reports).
 Physiological studies in humans.
 Meta-analyses of such studies.
Low certainty about the estimate of effect. Further
research is likely to have an impact on our conﬁdence
in the estimate of effect and is likely to change the
estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (e.g., jumping from air-
planes or tall structures), can represent high- or moderate-quality evidence. In such cases, the
rationale for the evidence rating exception should be explained by the Work Group and clearly
justiﬁed.
y“Well-designed, well-executed” refers to studies that directly address the question; use
adequate randomization, blinding, and allocation concealment; are adequately powered; use
intention-to-treat analyses; and have high follow-up rates.
zLimitations include concerns with the design and execution of a study that result in decreased
conﬁdence in the true estimate of the effect. Examples of such limitations include but are not
limited to: inadequate randomization, lack of blinding of study participants or outcome asses-
sors, inadequate power, outcomes of interest that are not prespeciﬁed for the primary out-
comes, low follow-up rates, and ﬁndings based on subgroup analyses. Whether the limitations
are considered minor or major is based on the number and severity of ﬂaws in design or
execution. Rules for determining whether the limitations are considered minor or major and how
they will affect rating of the individual studies will be developed collaboratively with the meth-
odology team.
xNonrandomized controlled studies refer to intervention studies where assignment to inter-
vention and comparison groups is not random (e.g., quasi-experimental study design).
jjObservational studies include prospective and retrospective cohort, case-control, and cross-
sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, randomized controlled
trials.
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cholesterol for the primary and secondary prevention of
ASCVD in women and men.
Because RCT data were used to identify those most likely
to beneﬁt from cholesterol-lowering statin therapy, the
recommendations will be of value to primary care clinicians
as well as specialists concerned with ASCVD prevention.
Importantly, the recommendations were designed to be
easy to use in the clinical setting, facilitating the imple-
mentation of a strategy of risk assessment and treatment
focused on the prevention of ASCVD. The present
guideline is intended to address treatment of adults (21
years of age) to complement the NHLBI cardiovascular
health risk-reduction guideline for children and adoles-
cents (4).
The members of the Expert Panel acknowledge the
important contributions arising from decades of genetic
and biochemical studies, observational epidemiological
and ecological studies, and in vitro and animal experi-
ments that associated higher low-density lipoproteincholesterol (LDL-C) levels with greater ASCVD risk.
These studies provided the rationale for RCTs, which in
turn demonstrated that lowering cholesterol levels reduced
ASCVD events and thereby established a central, causal
role of atherogenic cholesterol-containing lipoprotein
particles, particularly LDL, in the genesis of CHD and
ASCVD.
Other strategies for using drug therapy to reduce
ASCVD events have been advocated, including treat-
to-cholesterol target, lowest-is-best, and risk-based treat-
ment approaches. However, only 1 approach has been
evaluated in multiple RCTsdthe use of ﬁxed doses of
cholesterol-lowering drugs to reduce ASCVD risk. Because
the overwhelming body of evidence came from statin
Table 2. What’s New in the Guideline?*
1 Focus on ASCVD Risk Reduction: 4 Statin Beneﬁt Groups
1. This guideline is based on a comprehensive set of data from RCTs
from which 4 statin beneﬁt groups were identiﬁed that focus efforts
to reduce ASCVD events in secondary and primary prevention.
2. This guideline identiﬁes high-intensity and moderate-intensity
statin therapy for use in secondary and primary prevention.
2 A New Perspective on LDL-C and/or Non–HDL-C Treatment Goals
1. The Expert Panel was unable to ﬁnd RCT evidence to support
continued use of speciﬁc LDL-C or non–HDL-C treatment targets.
2. The appropriate intensity of statin therapy should be used to
reduce ASCVD risk in those most likely to beneﬁt.
3. Nonstatin therapies, as compared with statin therapy,
do not provide acceptable ASCVD risk-reduction beneﬁts relative
to their potential for adverse effects in the routine prevention
of ASCVD.
3 Global Risk Assessment for Primary Prevention
1. This guideline recommends use of the new Pooled Cohort Equations
to estimate 10-year ASCVD risk in both white and black men and
women.
2. By more accurately identifying higher-risk individuals for statin
therapy, the guideline focuses statin therapy on those most likely
to beneﬁt.
3. It also indicates, on the basis of RCT data, those high-risk groups
that might not beneﬁt.
4. This guideline recommends a discussion between clinicians
and patients before initiation of statin therapy.
4 Safety Recommendations
1. This guideline used RCTs to identify important safety
considerations in individuals receiving treatment of blood
cholesterol to reduce ASCVD risk.
2. Using RCTs to determine statin adverse effects facilitates
understanding of the net beneﬁt from statin therapy.
3. This guideline provides expert guidance on management of
statin-associated adverse effects, including muscle symptoms.
5 Role of Biomarkers and Noninvasive Tests
1. Treatment decisions in selected individuals who are not included
in the 4 statin beneﬁt groups may be informed by other factors as
recommended by the Risk Assessment Work Group and
Blood Cholesterol Expert Panel.
6 Future Updates to the Blood Cholesterol Guideline
1. This is a comprehensive guideline for the evidence-based treatment
of blood cholesterol to reduce ASCVD risk.
2. Future updates will build on this foundation to provide expert
guidance on the management of complex lipid disorders and
incorporate reﬁnements in risk stratiﬁcation based on critical
review of emerging data.
3. RCTs comparing alternative treatment strategies are needed in
order to inform future evidence-based guidelines for the optimum
ASCVD risk-reduction approach.
*See Appendix 5, for an expanded discussion of what’s new in the guideline.
ASCVD indicates atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; and RCT, randomized controlled trial.
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statin RCTs to develop evidence-based guidelines for the
reduction of ASCVD risk. We recognize that this repre-
sents a signiﬁcant departure from current strategies. This
should not come as a surprise to clinicians. The recent
guideline on heart failure has changed long-standing para-
digms on the basis of the evidence, and this guideline does
as well (5). Future RCTs will be needed to determine the
optimal treatment strategy to provide the greatest reduction
in ASCVD events with best margin of safety.
The Expert Panel acknowledges that our process did not
provide for a comprehensive approach to the detection,evaluation, and treatment of lipid disorders as was done in
the prior Adult Treatment Panel III Report (6). However,
the present guideline was never intended to be a compre-
hensive approach to lipid management for purposes other
than ASCVD risk reduction. A limited number of expert
opinion recommendations were made only when RCT
evidence was not present and after a thorough consider-
ation of what the Expert Panel had learned from the
RCTs. For the many questions about complex lipid dis-
orders that are beyond the scope of our systematic evidence
review, or for which little or no RCT data are available, it
is anticipated that clinicians with lipid expertise can
contribute to their management.
1.4. Methodology and Evidence Review
Although the Expert Panel was convened before the
Institute of Medicine reports on practice guidelines, our
evidence-based process followed most of the standards
from the Institute of Medicine report, “Clinical Practice
Guidelines We Can Trust” (1). The systematic review was
limited to RCTs with ASCVD outcomes and systematic
reviews and meta-analyses of RCTs with ASCVD out-
comes. Observational studies and those with <18 months
(CQ1 and CQ2) or <12 months (CQ3) of follow-up were
excluded. Support was provided by a methodology con-
tractor and a systematic review and general support con-
tractor and included the following steps:
 The Expert Panel constructed CQs relevant to
clinical practice.
 The Expert Panel identiﬁed (a priori) inclusion/
exclusion criteria for each CQ.
 An independent contractor developed a literature
search strategy, based on inclusion/exclusion criteria,
for each CQ.
 An independent contractor executed a systematic
electronic search of the published literature from
relevant bibliographic databases for each CQ. The
date range for the overall literature search was
January 1, 1995, through December 1, 2009. How-
ever, RCTs with hard ASCVD outcomes of myo-
cardial infarction (MI), stroke, and cardiovascular
death published after that date range were eligible
for consideration until the Expert Panel began de-
liberations on relevant recommendations.
 RCTs that met the inclusion criteria and were
independently graded as fair or good quality were
included in the evidence tables for the consideration
of the Expert Panel. RCTs that were graded as poor
quality were excluded.
 With the assistance of independent methodologists,
this evidence base was used to develop a series of
evidence statements graded on the level of the evi-
dence (high, medium, or low).
 The Expert Panel then synthesized the evidence state-
ments into treatment recommendations/summaries
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(recommend against), E (expert), and N (no
recommendation).
 The ﬁnal evidence statements and treatment rec-
ommendations were approved by at least a majority
of voting members of the Expert Panel.
 Guideline implementability appraisals, planned and
coordinated by the NHLBI Implementation Work
Group, were performed to identify and address bar-
riers to guideline implementation.
In addition, the Expert Panel was able to include major
RCTs and meta-analyses of RCTs published through July
2013 in our discussion and as part of the process of
determining ACC/AHA grading of the NHLBI expert-
level recommendations.2. Overview of the Guideline
The RCTs identiﬁed in the systematic evidence review
indicated a consistent reduction in ASCVD events from
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhib-
itor (statin) therapy in secondary- and primary-prevention
populations, with the exception of no ASCVD event
reduction when statin therapy was initiated in those with
New York Heart Association class II to IV heart failure or
those receiving maintenance hemodialysis. The RCTs
either compared ﬁxed doses of statins with placebo or
untreated controls, or compared ﬁxed doses of higher-
intensity statins with moderate-intensity statins. These
trials were not designed to evaluate the effect of titrated
(dose-adjusted) statin treatment to achieve prespeciﬁed
LDL-C or non–HDL-C goals.Figure 1. Overview of the Expert Panel’s Guideline
RCTs indicates randomized controlled trials.Therefore, the Expert Panel was unable to ﬁnd RCT
evidence to support titrating cholesterol-lowering drug
therapy to achieve target LDL-C or non–HDL-C levels,
as recommended by Adult Treatment Panel III (6–8).
Notably, the Expert Panel did ﬁnd RCT evidence that use
of therapy (e.g., niacin) to additionally lower non–HDL-C,
once an LDL-C target was achieved, did not further
reduce ASCVD outcomes (9). The Expert Panel also
found extensive RCT evidence that the appropriate in-
tensity of statin therapy should be used to reduce
ASCVD risk in those most likely to beneﬁt. The work of
the Expert Panel was informed by the reports of the
Lifestyle Management (10) and Risk Assessment Work
Groups (11) (Figure 1). A summary of the major rec-
ommendations for the treatment of cholesterol to reduce
ASCVD risk is provided in Table 3.2.1. Lifestyle as the Foundation for
ASCVD Risk-Reduction Efforts
It must be emphasized that lifestyle modiﬁcation (i.e.,
adhering to a heart-healthy diet, regular exercise habits,
avoidance of tobacco products, and maintenance of a
healthy weight) remains a crucial component of health
promotion and ASCVD risk reduction, both prior to and in
concert with the use of cholesterol-lowering drug therapies.
Healthy diet or lifestyle modiﬁcations were recommended
as background therapy for the RCTs of cholesterol-
lowering drug therapy. See the “2013 AHA/ACC Guide-
line on Lifestyle Management to Reduce Cardiovascular
Risk” (10) for lifestyle recommendations for healthy adults.
Drug therapy for lifestyle-related risk factors such as hy-
pertension is often needed and smoking should be avoided.
Table 3. Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
(See Tables 4, 8, 9, and 10 for the complete recommendations; and Table 5 for deﬁnition of statin intensity)
Recommendations ACC/AHA COR ACC/AHA LOE
A. Heart-healthy lifestyle habits should be encouraged for all individuals
B. The appropriate intensity of statin therapy should be initiated or continued:
1. Clinical ASCVD*
a. Age 75 y and no safety concerns: High-intensity statin I A
b. Age >75 y or safety concerns: Moderate-intensity statin I A
2. Primary prevention – Primary LDL-C ‡190 mg/dL
a. Rule out secondary causes of hyperlipidemia (Table 6) I B
b. Age 21 y: High-intensity statin I B
c. Achieve at least a 50% reduction in LDL-C IIa B
d. LDL-C lowering nonstatin therapy may be considered to further reduce LDL-C IIb C
3. Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL
a. Moderate-intensity statin I A
b. Consider high-intensity statin when 7.5% 10-y ASCVD risk using the Pooled Cohort Equationsy IIa B
4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
a. Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin;
estimate risk every 4–6 y
I B
b. To determine whether to initiate a statin, engage in a clinician-patient discussion of the potential for ASCVD risk reduction,
adverse effects, drug–drug interactions, and patient preferences
c. Re-emphasize heart-healthy lifestyle habits and address other risk factors
IIa C
i. ‡7.5% 10-y ASCVD risk: Moderate- or high-intensity statin I A
ii. 5 to <7.5% 10-y ASCVD risk: Consider moderate-intensity statin IIa B
iii. Other factors may be consideredz: LDL-C 160 mg/dL, family history of premature ASCVD, hs-CRP 2.0 mg/L,
CAC score 300 Agaston units, ABI <0.9, or lifetime ASCVD risk
IIb C
5. Primary prevention when LDL-C <190 mg/dL and age <40 or >75 y, or <5% 10-y ASCVD risk
a. Statin therapy may be considered in selected individualsz
IIb C
6. Statin therapy is not routinely recommended for individuals with NYHA class II-IV heart failure or who are receiving
maintenance hemodialysis
C. Regularly monitor adherence to lifestyle and drug therapy with lipid and safety assessments
1. Assess adherence, response to therapy, and adverse effects within 4–12 wk following statin initiation or change in therapy I A
a. Measure a fasting lipid panel I A
b. Do not routinely monitor ALT or CK unless symptomatic IIa C
c. Screen and treat type 2 diabetes according to current practice guidelines. Heart-healthy lifestyle habits should be encouraged
to prevent progression to diabetes
I B
d. Anticipated therapeutic response: approximately 50% reduction in LDL-C from baseline for high-intensity statin and
30% to <50% for moderate-intensity statin
IIa B
i. Insufﬁcient evidence for LDL-C or non–HDL-C treatment targets from RCTs
ii. For those with unknown baseline LDL-C, an LDL-C <100 mg/dL was observed in RCTs of high-intensity statin therapy
e. Less than anticipated therapeutic response:
i. Reinforce improved adherence to lifestyle and drug therapy I A
ii. Evaluate for secondary causes of hyperlipidemia if indicated (Table 6) I A
iii. Increase statin intensity, or if on maximally-tolerated statin intensity, consider addition of nonstatin therapy in selected
high-risk individualsx
IIb C
f. Regularly monitor adherence to lifestyle and drug therapy every 3–12 mo once adherence has been established. Continue
assessment of adherence for optimal ASCVD risk reduction and safety
I A
D. In individuals intolerant of the recommended intensity of statin therapy, use the maximally tolerated intensity of
statin.
I B
1. If there are muscle or other symptoms, establish that they are related to the statin IIa B
2. For speciﬁc recommendations on managing muscle symptoms (Table 8)
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of
atherosclerotic origin.
yEstimated 10-year or “hard” ASCVD risk includes ﬁrst occurrence of nonfatal MI, CHD death, and nonfatal and fatal stroke as used by the Risk Assessment Work Group in developing the Pooled Cohort
Equations (http://my.americanheart.org/cvriskcalculator and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx).
zThese factors may include primary LDL-C 160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset <55 years of age in a ﬁrst-degree male relative or <65
years of age in a ﬁrst-degree female relative; hs-CRP 2 mg/L; CAC score 300 Agatston units or 75th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/
CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional factors that might aid in individual risk assessment could be identiﬁed in the future.
xHigh-risk individuals include those with clinical ASCVD, an untreated LDL-C 190 mg/dL suggesting genetic hypercholesterolemia, or individuals with diabetes 40 to 75 years of age and LDL-C 70 to
189 mg/dL.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ALT, alanine aminotransferase, a test of hepatic function; ASCVD, atherosclerotic cardiovascular
disease; CAC, coronary artery calcium; CHD, coronary heart disease; CK, creatine kinase, a test of muscle injury; COR, Class of Recommendation; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-
sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; NYHA, New York Heart Association; RCTs, randomized
controlled trials; and TIA, transient ischemic attack.
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28972.2. Initiation of Statin Therapy
The Expert Panel found extensive and consistent evidence
supporting the use of statins for the prevention of ASCVD
in many higher-risk primary- and all secondary-prevention
individuals without New York Heart Association class
II–IV heart failure who were not receiving hemodialysis.
In the RCTs reviewed, initiation of moderate-intensity
therapy (lowering LDL-C by approximately 30%
to <50%) or high-intensity statin therapy (lowering LDL-C
by approximately 50%) is a critical factor in reducing
ASCVD events. Moreover, statin therapy reduces ASCVD
events across the spectrum of baseline LDL-C
levels 70 mg/dL. In addition, the relative reduction
in ASCVD risk is consistent for primary and secondary
prevention and for various patient subgroups. Of note,
the absolute reduction in ASCVD events is proportional
to baseline absolute ASCVD risk. Therefore, statin
therapy is recommended for individuals at increased
ASCVD risk who are most likely to experience a net
beneﬁt in terms of the potential for ASCVD risk
reduction and the potential for adverse effects (Table 3;
Figure 2).
On the basis of this large and consistent body of evi-
dence, 4 major statin beneﬁt groups were identiﬁed for
whom the ASCVD risk reduction clearly outweighs the
risk of adverse events based on a strong body of evidence.
These are 1) secondary prevention in individuals with
clinical ASCVD, 2) primary prevention in individuals with
primary elevations of LDL-C 190 mg/dL, 3) primary
prevention in individuals with diabetes 40 to 75 years of
age who have LDL-C 70 to 189 mg/dL, and 4) primary
prevention in individuals without diabetes and with esti-
mated 10-year ASCVD risk 7.5%, 40 to 75 years of age
who have LDL-C 70 to 189 mg/dL. Moderate evidence
supports the use of statins for primary prevention in in-
dividuals with 5% to <7.5% 10-year ASCVD risk, 40 to
75 years of age with LDL-C 70 to 189 mg/dL. Selected
individuals with <5% 10-year ASCVD risk, or <40 or
>75 years of age may also beneﬁt from statin therapy.
Clinicians and patients should engage in a discussion of the
potential for ASCVD risk-reduction beneﬁts, adverse ef-
fects, drug–drug interactions, and consider patient prefer-
ences for treatment. This discussion also provides the
opportunity to re-emphasize healthy-lifestyle habits and
address other risk factors.
Clinical ASCVD is deﬁned by the inclusion criteria for
the secondary-prevention statin RCTs (acute coronary
syndromes, a history of MI, stable or unstable angina,
coronary or other arterial revascularization, stroke, tran-
sient ischemic attack, or peripheral arterial disease pre-
sumed to be of atherosclerotic origin). For primary
prevention in individuals without clinical ASCVD or
diabetes who have an LDL-C 70 to 189 mg/dL, the
estimated absolute 10-year risk of ASCVD (deﬁned as
nonfatal MI, CHD death, or nonfatal and fatal stroke)should be used to guide the initiation of statin therapy.
The 10-year ASCVD risk should be estimated with the
Pooled Cohort Equations (Section 4.7). For the primary
prevention of ASCVD in individuals with diabetes
(diabetes mellitus type 1 and type 2), estimated 10-year
ASCVD risk can also be used to guide the intensity of
statin therapy. For those with clinical ASCVD or with
LDL-C 190 mg/dL who are already in a statin beneﬁt
group, it is not appropriate to estimate 10-year ASCVD
risk. In primary prevention, additional factors may in-
ﬂuence ASCVD risk in those for whom a risk-based
decision is unclear. These include a primary LDL-
C 160 mg/dL or other evidence of genetic hyperlip-
idemias, family history of premature ASCVD with
onset <55 years of age in a ﬁrst-degree male relative
or <65 years of age in a ﬁrst-degree female relative, high-
sensitivity C-reactive protein 2 mg/L, coronary artery
calcium score 300 Agatston units or 75th percentile
for age, sex, and ethnicity (for additional information,
see http://www.mesa-nhlbi.org/CACReference.aspx.), ankle-
brachial index <0.9, and elevated lifetime risk of
ASCVD.
The ﬁndings support the use of statins to prevent both
nonfatal and fatal ASCVD events. Such an approach can
reduce the large burden of disability from nonfatal stroke
(for which women are at higher risk than men) and
nonfatal CHD events. Primary and secondary prevention
of ASCVD with statins can positively impact rising
healthcare costs. In addition, a high level of evidence was
found that statins reduce total mortality in individuals with
a history of prior ASCVD events (e.g., secondary-
prevention settings). In individuals with no prior history
of ASCVD events (e.g., primary-prevention settings),
there is moderate evidence that statins reduce total mor-
tality in individuals at increased ASCVD risk. It should be
noted that 2 meta-analyses published after the completion
of the Expert Panel’s systematic review provide strong
evidence that statins reduce total mortality in primary
prevention (12,13).3. Critical Questions and Conclusions
3.1. Identiﬁcation of CQs
Although limited to 3 CQs, these questions were consid-
ered the most important to answer in order to identify
whom to treat and with what treatment(s) and to consider
how intensively the treatments should be used. The ﬁrst 2
CQs evaluated the evidence for LDL-C and non–HDL-C
goals for the secondary and primary prevention of ASCVD
with cholesterol-lowering drug therapy. Titration to spe-
ciﬁc LDL-C goals has been considered a fundamental
therapeutic strategy in deciding on the adequacy of
cholesterol-lowering therapy for secondary and primary
prevention. Therefore, a comprehensive systematic review
Yes
Age ≤75 y
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)Age ≥21 y and a candidate 
for statin therapy
Yes
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)
Yes
No
Moderate-intensity statin
No
Primary prevention 
(No diabetes, LDL-C 70 to 189 mg/dL, and not receiving statin therapy)
Estimate 10-y ASCVD risk every 4-6 y
using Pooled Cohort Equations†
No
In selected individuals, additional 
factors may be considered to inform 
treatment decision making§
Heart-healthy lifestyle habits are the foundation of ASCVD prevention
(See 2013 AHA/ACC Lifestyle Management Guideline)
Yes
Estimated 10-y ASCVD risk ≥7.5%†
High-intensity statin
Age >75 y OR if not candidate for 
high-intensity statin
Moderate-intensity statin
Yes
Yes
Clinical 
ASCVD
LDL-C ≥190 
mg/dL
Diabetes
LDL-C 70-189 mg/dL
Age 40-75 y
Definitions of High- and Moderate-
Intensity Statin Therapy*
(See Table 5)
High
Daily dose lowers 
LDL-C by approx. 
≥50%
Moderate
Daily dose lowers 
LDL-C by approx. 
30% to <50%
≥7.5%
10-y ASCVD risk
(Moderate- or high-
intensity statin)
5% to <7.5%
10-y ASCVD risk
(Moderate-intensity 
statin)
<5%
10-y ASCVD 
risk‡
Age <40 or >75 y 
and LDL-C <190 
mg/dL‡
Clinician-Patient Discussion
Prior to initiating statin therapy, discuss:
    1. Potential for ASCVD risk-reduction benefits║
    2. Potential for adverse effects and drug–drug interactions¶
    3. Heart-healthy lifestyle
    4. Management of other risk factors
    5. Patient preferences
    6. If decision is unclear, consider primary LDL-C ≥160 mg/dL, family history of premature 
        ASCVD, lifetime ASCVD risk, abnormal CAC score or ABI, or hs-CRP ≥2 mg/L§
No to statin
Yes to statin
 Encourage adherence to lifestyle 
 Initiate statin at appropriate intensity
 Manage other risk factors
 Monitor adherence* (See Fig 5)
 Emphasize adherence to lifestyle 
 Manage other risk factors
 Monitor adherence
DM age <40 
or >75 y or 
LDL-C <70 
mg/dL
Regularly monitor adherence to 
lifestyle and drug therapy with 
lipid and safety assessments 
(See Fig 5)
Figure 2. Summary of Statin Initiation Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
(See Figures 3, 4, and 5 for More Detailed Management Information)
Colors correspond to the Classes of Recommendation in Table 1. Assessment of the potential for beneﬁt and risk from statin therapy for ASCVD prevention provides the
framework for clinical decision making incorporating patient preferences.
*Percent reduction in LDL-C can be used as an indication of response and adherence to therapy, but is not in itself a treatment goal.
yThe Pooled Cohort Equations can be used to estimate 10-year ASCVD risk in individuals with and without diabetes. The estimator within this application should be used to
inform decision making in primary prevention patients not on a statin.
zConsider moderate-intensity statin as more appropriate in low-risk individuals.
xFor those in whom a risk assessment is uncertain, consider factors such as primary LDL-C 160 mg/dL or other evidence of genetic hyperlipidemias, family history of
premature ASCVD with onset <55 years of age in a ﬁrst-degree male relative or <65 years of age in a ﬁrst-degree female relative, hs-CRP 2 mg/L, CAC score 300 Agatston
units, or 75th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/CACReference.aspx), ABI <0.9, or lifetime risk of ASCVD.
Additional factors that may aid in individual risk assessment may be identiﬁed in the future.
kPotential ASCVD risk-reduction beneﬁts. The absolute reduction in ASCVD events from moderate- or high-intensity statin therapy can be approximated by multiplying the estimated
10-year ASCVD risk by the anticipated relative-risk reduction from the intensity of statin initiated (w30% for moderate-intensity statin orw45% for high-intensity statin therapy).
The net ASCVD risk-reduction beneﬁt is estimated from the number of potential ASCVD events prevented with a statin, compared to the number of potential excess adverse effects.
{Potential adverse effects. The excess risk of diabetes is the main consideration in w0.1 excess cases per 100 individuals treated with a moderate-intensity statin for
1 year and w0.3 excess cases per 100 individuals treated with a high-intensity statin for 1 year. In RCTs, both statin-treated and placebo-treated participants experienced the
same rate of muscle symptoms. The actual rate of statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms attributed to statin therapy should
be evaluated (see Table 8, Safety Recommendation 8).
ABI indicates ankle-brachial index; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density
lipoprotein cholesterol; MI, myocardial infarction; and RCT, randomized controlled trial.
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2899of the evidence base supporting this concept was essential.
The third CQ had several objectives:
 Identify groups of patients who will beneﬁt from
pharmacological treatment,
 Deﬁne the pharmacological treatment(s) for which
there is the best evidence of net beneﬁt, and
 Provide guidance on the appropriate intensity of
pharmacological treatment to reduce ASCVD risk.
3.1.1. CQ1: LDL-C and Non–HDL-C Goals
in Secondary Prevention
CQ1:What is the evidence for LDL-C and non–HDL-C
goals for the secondary prevention of ASCVD?
The Expert Panel reviewed 19 RCTs to answer CQ1.
Although CQ1 is supported conceptually by an extrapo-
lation of observational studies and observational data from
RCTs, no data were identiﬁed for treatment or titration
to a speciﬁc LDL-C goal in adults with clinical ASCVD.
The majority of studies conﬁrming the efﬁcacy of
cholesterol reduction in improving clinical outcomes in
patients with clinical ASCVD used a single ﬁxed-dose
statin to lower LDL-C levels. In the 4S trial, 37% had
the dose of simvastatin raised from 20 mg/d to 40 mg/d to
achieve a total cholesterol level <200 mg/dL (16). The
Expert Panel was unable to ﬁnd any RCTs that evaluated
titration of all individuals in a treatment group to speciﬁc
LDL-C targets <100 mg/dL or <70 mg/dL, nor were any
RCTs comparing 2 LDL-C treatment targets identiﬁed.
No statin RCTs reporting on-treatment non–HDL-C
levels were identiﬁed. (In CQ3, statin-nonstatin combina-
tion therapy was evaluated.)
3.1.2. CQ2: LDL-C and Non–HDL-C Goals in
Primary Prevention
CQ2: What is the evidence for LDL-C and non–HDL-C
goals for the primary prevention of ASCVD?
The Expert Panel reviewed 6 RCTs. The 4 studies con-
ﬁrming the efﬁcacy of cholesterol reduction in improving
clinical outcomes in patients without ASCVD used ﬁxed-
dose statin therapy to lower LDL-C levels. In the
AFCAPS-TEXCAPS (Air Force/Texas Coronary
Atherosclerosis Prevention Study) trial (17), in 50% of
participants, the lovastatin dose was raised from 20 mg to
40 mg to achieve an LDL-C level <110 mg/dL. In the
MEGA (Management of Elevated Cholesterol in the
Primary Prevention Group of Adult Japanese) trial (18),
the dose of pravastatin could be uptitrated from 10 mg to
20 mg to achieve a total cholesterol level <220 mg/dL.
The Expert Panel did not ﬁnd any RCTs that evaluated
titration of all individuals in a treatment group to speciﬁc
LDL-C targets <100 mg/dL or <70 mg/dL, nor were any
RCTs comparing 2 LDL-C treatment targets identiﬁed.
No trials reported on-treatment non–HDL-C levels.3.1.3. CQ3: Efﬁcacy and Safety of
Cholesterol-Lowering Medications
CQ3: For primary and secondary prevention, what is
the impact on lipid levels, effectiveness, and safety of
speciﬁc cholesterol-modifying drugs used for lipid
management in general and in selected subgroups?
The populations examined included primary-prevention
adult patients who could not have a diagnosis of CHD
or cardiovascular disease. Interventions included pharma-
cotherapy with single-drug therapies or combination-drug
therapies with any drug therapy used for treating blood
cholesterol, including statins, ﬁbrates (fenoﬁbrate, gemﬁ-
brozil), nicotinic acid (niacin in immediate-, slow-, or
extended-release form), bile acid sequestrants, ezetimibe,
omega-3 fatty acids (also called marine fatty acids, in-
cluding eicosapentaenoic acid alone, docosahexanoic acid
alone, eicosapentaenoic acid plus docosahexanoic acid, and
alpha-linolenic acid). There were no ASCVD outcomes
identiﬁed for plant sterols, sterol esters, stanols, or stanol
esters. A single ASCVD outcomes trial (19) used Xuez-
hikang, an extract from red yeast Chinese rice, which was
not available in the United States during the timeframe
for evidence review, so no recommendations were made
regarding its use.
The recommendations synthesize the evidence retrieved
for answering CQ3, along with the evidence from the trials
included in CQ1 and CQ2, to guide the use of cholesterol-
lowering drugs for secondary or primary prevention of
ASCVD.
4. Statin Treatment: Recommendations
For each recommendation, the grades of the recom-
mendation by both the NHLBI and ACC/AHA
methods are provided. Major treatment recommenda-
tions are listed in Table 4, and statin intensities are
deﬁned in Table 5. The safety (statin and nonstatin)
recommendations are in Section 5. A complete listing
of the evidence statements supporting each recom-
mendation, along with the references, is provided in
Appendix 4.
4.1. Intensity of Statin Therapy in
Primary and Secondary Prevention
The Expert Panel deﬁnes the intensity of statin therapy
on the basis of the average expected LDL-C response to
a speciﬁc statin and dose. “High-intensity,” “moderate-
intensity,” and “low-intensity” statin therapy deﬁnitions
were derived from the systematic reviews for CQ1 and
CQ2. The basis for differentiation among speciﬁc statins
and doses arose from the RCTs included in CQ1, where
there was a high level of evidence that high-intensity
statin therapy with atorvastatin 40 mg to 80 mg
reduced ASCVD risk more than moderate-intensity
Table 4. Recommendations for Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adultsd
Statin Treatment (High, Moderate, and Low Statin Intensities are Deﬁned in Table 5)
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Treatment Targets
1. The Expert Panel makes no recommendations for or
against speciﬁc LDL-C or non–HDL-C targets for the
primary or secondary prevention of ASCVD.
N (No recommendation) 1–4 d d
Secondary Prevention
1. High-intensity statin therapy should be initiated or
continued as ﬁrst-line therapy in women and men
75 years of age who have clinical ASCVD*, unless
contraindicated.
A (Strong) 1,6–8,10–23,26–28 I A
2. In individuals with clinical ASCVD* in whom high-
intensity statin therapy would otherwise be used, when
high-intensity statin therapy is contraindicatedy or
when characteristics predisposing to statin-associated
adverse effects are present, moderate-intensity statin
should be used as the second option if tolerated
(Table 8 for Safety of Statins, Recommendation 1).
A (Strong) 13–22,24,27,28 I A
3. In individuals with clinical ASCVD >75 years of age, it
is reasonable to evaluate the potential for ASCVD risk-
reduction beneﬁts and for adverse effects and drug–drug
interactions and to consider patient preferences when
initiating a moderate- or high-intensity statin. It is
reasonable to continue statin therapy in those who are
tolerating it.
E (Expert Opinion) d IIa B
(16,20–43)
Primary Prevention in Individuals ‡21 Years of Age With LDL-C ‡190 mg/dL
1. Individuals with LDL-C 190 mg/dL or triglycerides
500 mg/dL should be evaluated for secondary causes
of hyperlipidemia (Table 6).
B (Moderate) 75 Iz B
(44,45)
2. Adults 21 years of age with primary LDL-C 190 mg/
dL should be treated with statin therapy (10-year ASCVD
risk estimation is not required):
 Use high-intensity statin therapy unless
contraindicated.
 For individuals unable to tolerate high-intensity statin
therapy, use the maximum tolerated statin intensity.
B (Moderate) 6,19,28,33–35,37,38 Ix B
3. For individuals 21 years of age with an untreated
primary LDL-C 190 mg/dL, it is reasonable to intensify
statin therapy to achieve at least a 50% LDL-C reduction.
E (Expert Opinion) d IIa B
(20,46–50)
4. For individuals 21 years of age with an untreated pri-
mary LDL-C 190 mg/dL, after the maximum intensity
of statin therapy has been achieved, addition of a non-
statin drug may be considered to further lower LDL-C.
Evaluate the potential for ASCVD risk-reduction beneﬁts,
adverse effects, and drug–drug interactions, and consider
patient preferences.
E (Expert Opinion) d IIb C
(51)
Primary Prevention in Individuals With Diabetes and LDL-C 70–189 mg/dL
1. Moderate-intensity statin therapy should be initiated
or continued for adults 40–75 years of age with diabetes.
A (Strong) 19,29–34,40 I A
2. High-intensity statin therapy is reasonable for adults
40–75 years of age with diabetes with a 7.5%
estimated 10-year ASCVD riskk unless contraindicated.
E (Expert Opinion) d IIa B
(49,52)
3. In adults with diabetes, who are <40 years of age or
>75 years of age, or with LDL <70 mg/dL it is reason-
able to evaluate the potential for ASCVD beneﬁts and for
adverse effects and drug–drug interactions and to
consider patient preferences when deciding to initiate,
continue, or intensify statin therapy.
E (Expert Opinion) d IIa C
(53–62)
Continued on the next page
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Table 4. Continued
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Primary Prevention in Individuals Without Diabetes and With LDL-C 70–189 mg/dL
1. The Pooled Cohort Equations should be used to estimate
10-year ASCVDk risk for individuals with LDL-C 70–189
mg/dL without clinical ASCVD* to guide initiation of
statin therapy for the primary prevention of ASCVD.
E (Expert Opinion) d I B
(11)
2. Adults 40–75 years of age with LDL-C 70–189 mg/dL,
without clinical ASCVD* or diabetes, and with an
estimated 10-year ASCVDk risk 7.5% should be treated
with moderate- to high-intensity statin therapy.
A (Strong) 28,34–36,38,42–44,
47,49–56,76
I A
3. It is reasonable to offer treatment with a moderate-
intensity statin to adults 40–75 years of age, with LDL-C
70–189 mg/dL, without clinical ASCVD* or diabetes, and
with an estimated 10-year ASCVDk risk of 5% to <7.5%.
C (Weak) 28,34–36,38,42–44,
47,49–56,76
IIa B
4. Before initiation of statin therapy for the primary pre-
vention of ASCVD in adults with LDL-C 70–189 mg/dL
without clinical ASCVD* or diabetes, it is reasonable for
clinicians and patients to engage in a discussion that
considers the potential for ASCVD risk-reduction beneﬁts
and for adverse effects and drug–drug interactions, as
well as patient preferences for treatment.
E (Expert Opinion) d IIa C
(63)
5. In adults with LDL-C <190 mg/dL who are not otherwise
identiﬁed in a statin beneﬁt group, or for whom after
quantitative risk assessment a risk-based treatment
decision is uncertain, additional factors{ may be
considered to inform treatment decision making. In
these individuals, statin therapy for primary prevention
may be considered after evaluation of the potential for
ASCVD risk-reduction beneﬁts, adverse effects, and drug–
drug interactions and consider patient preferences.
E (Expert Opinion) d IIb C
(11,13)
Heart Failure and Hemodialysis
1. The Expert Panel makes no recommendations regarding
the initiation or discontinuation of statins in patients with
NYHA class II–IV ischemic systolic heart failure or in pa-
tients on maintenance hemodialysis.
N (No Recommendation) 71,72 d d
*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of
atherosclerotic origin.
yContraindications, warnings, and precautions are deﬁned for each statin according to the manufacturer’s prescribing information (64–70).
zIndividuals with secondary causes of hyperlipidemia were excluded from RCTs reviewed. A triglyceride level 500 mg/dL was an exclusion criterion for almost all RCTs. Therefore, ruling out secondary
causes is necessary to avoid inappropriate statin therapy.
xNo RCTs included only individuals with LDL-C 190 mg/dL. However, many trials did include individuals with LDL-C 190 mg/dL, and all of these trials consistently demonstrated a reduction in ASCVD
events. In addition, the Cholesterol Treatment Trialists meta-analyses have shown that each 39-mg/dL reduction in LDL-C with statin therapy reduced ASCVD events by 22%, and the relative reductions in
ASCVD events were consistent across the range of LDL-C levels. Therefore, individuals with primary LDL-C 190 mg/dL should be treated with statin therapy.
kEstimated 10-year or “hard” ASCVD risk includes ﬁrst occurrence of nonfatal MI, coronary heart disease death, and nonfatal and fatal stroke as used by the Risk Assessment Work Group in developing
the Pooled Cohort Equations.
{These factors may include primary LDL-C 160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset<55 years of age in a ﬁrst-degree male relative or <65
years of age in a ﬁrst-degree female relative; high-sensitivity C-reactive protein 2 mg/L; CAC score 300 Agatston units or 75th percentile for age, sex, and ethnicity (for additional information, see
http://www.mesa-nhlbi.org/CACReference.aspx); ABI <0.9; or lifetime risk of ASCVD. Additional factors that might aid in individual risk assessment could be identiﬁed in the future.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; COR, Class of
Recommendation; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; NYHA, New York Heart
Association; RCTs, randomized controlled trials; TIA, transient ischemic attack; and d, not applicable.
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2901statin therapy with atorvastatin 10 mg, pravastatin 40 mg,
or simvastatin 20 mg to 40 mg twice daily. Classifying
speciﬁc statins and doses by the percent reduction in
LDL-C level is based on evidence that the relative
reduction in ASCVD risk from statin therapy is related to
the degree by which LDL-C is lowered. However, no
variation in the relative reduction in ASCVD risk was
observed after the data were adjusted for LDL-C reduc-
tion. Furthermore, there is no differentiation between the
speciﬁc statins and doses used in primary- and secondary-
prevention RCTs, according to a high level of evidence
that statins reduce ASCVD risk similarly in both
populations.Percent reductions in LDL-C for a speciﬁc statin and
dose were calculated for the RCTs included in individual
meta-analyses conducted by the Cholesterol Treatment
Trialists (CTT) in 2010 (20), in which statin therapy
reduced ASCVD events. High-intensity statin therapy
on average lowers LDL-C by approximately 50%,
moderate-intensity statin therapy lowers LDL-C by
approximately 30% to <50%, and lower-intensity statin
therapy lowers LDL-C by <30% (Table 5).
4.2. LDL-C and Non–HDL-C Treatment Goals
The Expert Panel did not ﬁnd evidence to support titrating
cholesterol-lowering drug therapy to achieve optimal
Table 5. High-, Moderate-, and Low-Intensity Statin Therapy (Used in the RCTs Reviewed by the Expert Panel)*
High-Intensity Statin Therapy Moderate-Intensity Statin Therapy Low-Intensity Statin Therapy
Daily dose lowers LDL-C, on average,
by approximately 50%
Daily dose lowers LDL-C, on average,
by approximately 30% to <50%
Daily dose lowers LDL-C,
on average, by <30%
Atorvastatin (40y)–80 mg
Rosuvastatin 20 (40) mg
Atorvastatin 10 (20) mg
Rosuvastatin (5) 10 mg
Simvastatin 20–40 mgz
Pravastatin 40 (80) mg
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg BID
Pitavastatin 2–4 mg
Simvastatin 10 mg
Pravastatin 10–20 mg
Lovastatin 20 mg
Fluvastatin 20–40 mg
Pitavastatin 1 mg
Boldface type indicates speciﬁc statins and doses that were evaluated in RCTs (16–18,46–49,64–75,77) included in CQ1, CQ2, and the Cholesterol Treatment Trialists 2010 meta-analysis included in
CQ3 (20). All of these RCTs demonstrated a reduction in major cardiovascular events. Italic type indicates statins and doses that have been approved by the FDA but were not tested in the RCTs reviewed.
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice. There might be a biological basis for a less-than-average response.
yEvidence from 1 RCT only: down-titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental Decrease through Aggressive Lipid Lowering) study (47).
zAlthough simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including
rhabdomyolysis.
BID indicates twice daily; CQ, critical question; FDA, Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; and RCTs, randomized controlled trials.
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2902LDL-C or non–HDL-C levels because the clinical trials
were essentially ﬁxed-dose trials (CQ1 and CQ2). Dosage
increases did occur in a few RCTs with the intent of
maximizing statin therapy. Therefore, these were not truly
tests of deﬁning optimal goals for LDL-C in primary and
secondary prevention because not all individuals in the
statin treatment groups received drug therapy titrated
to achieve a speciﬁc LDL-C or non–HDL-C goal, nor
were speciﬁc treatment targets compared. One RCT in
CQ3 was identiﬁed that showed no additional ASCVD
event reduction from the addition of nonstatin therapy to
further lower non–HDL-C levels once an LDL-C goal
had been reached. In AIM-HIGH (Atherothrombosis
Intervention in Metabolic Syndrome With Low HDL/
High Triglycerides and Impact on Global Health Out-
comes), the additional reduction in non–HDL-C levels
(as well as further reductions in apolipoprotein B, lipo-
protein[a], and triglycerides in addition to HDL-C
increases) with niacin therapy did not further reduce
ASCVD risk in individuals treated to LDL-C levels of 40
to 80 mg/dL (9).
Therefore, given the absence of data on titration of drug
therapy to speciﬁc goals, no recommendations are made for
or against speciﬁc LDL-C or non–HDL-C goals for the
primary or secondary prevention of ASCVD.
4.3. Secondary Prevention
Women and men with clinical ASCVD (deﬁned from the
RCT inclusion criteria as acute coronary syndromes; history
of MI, stable or unstable angina, coronary or other arterial
revascularization, stroke, transient ischemic attack, or pe-
ripheral arterial disease presumed to be of atherosclerotic
origin) arterial revascularization, stroke, transient ischemic
attack, or peripheral arterial disease presumed to be of
atherosclerotic origin are at increased risk for recurrent
ASCVD and ASCVD death. An extensive body of evi-
dence demonstrates that high-intensity statin therapy re-
duces ASCVD events more than moderate-intensity statin
therapy (Table 4) in individuals with clinical ASCVD.High-intensity statin therapy should be initiated for
adults 75 years of age with clinical ASCVD who are not
receiving statin therapy, or the intensity should be increased
in those receiving a low- or moderate-intensity statin, un-
less they have a history of intolerance to high-intensity
statin therapy or other characteristics that could inﬂuence
safety (Section 5). This is consistent with RCT data. In
2 trials, patients were previously treated with a moderately
intensive statin (46,47), and in 2 trials, 75% to 97% of
patients had not received prior statin therapy (48,78). The
high-intensity statins atorvastatin 80 mg and rosuvastatin
20 mg daily reduce LDL-C 50% on average and have
been shown to reduce ASCVD events in RCTs.
Although atorvastatin 40 mg reduces LDL-C by app-
roximately 50%, this dose was used in only 1 RCT if the
participant was unable to tolerate atorvastatin 80 mg/dL.
Whether an individual receiving atorvastatin 40 mg should
be uptitrated to atorvastatin 80 mg should be based on the
potential for an ASCVD risk-reduction beneﬁt and the
potential for adverse effects, drug–drug interactions, and
consider patient preferences.
In individuals with clinical ASCVD in whom high-
intensity statin therapy would otherwise be used, either
whenhigh-intensity statin therapy is contraindicated orwhen
characteristics predisposing to statin-associated adverse ef-
fects are present, moderate-intensity statin should be used as
the second option, if tolerated (Section 5). In the relatively
few individuals >75 years of age who were included in
RCTs of high- versus moderate-intensity statin therapy,
there was no clear evidence of an additional reduction in
ASCVD events from high-intensity statin therapy. In
contrast, individuals >75 years of age did experience a
reduction in ASCVD events in the trials of mostly moderate-
intensity statin therapy, as compared with control. Therefore,
moderate-intensity statin therapy should be considered for
individuals>75 years of age with clinicalASCVD.However,
in acknowledgment that older participants in RCTs were
likely tobehealthier thanmanyolder individuals in the general
population, the use of statin therapy should be individualized
Figure 3. Initiating Statin Therapy in Individuals With Clinical ASCVD
Colors correspond to the Classes of Recommendation in Table 1.
*Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level 220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a
secondary etiology. If nonfasting triglycerides are 500 mg/dL, a fasting lipid panel is required.
yIt is reasonable to evaluate the potential for ASCVD beneﬁts and for adverse effects, and to consider patient preferences, in initiating or continuing a moderate- or high-intensity
statin in individuals with ASCVD who are >75 years of age.
ALT indicates alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CK, creatine kinase; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein
cholesterol; and ULN, upper limit of normal.
Table 6. Secondary Causes of Hyperlipidemia Most
Commonly Encountered in Clinical Practice
Secondary Cause Elevated LDL-C
Elevated
Triglycerides
Diet Saturated or trans fats,
weight gain, anorexia
nervosa
Weight gain, very-low-fat
diets, high intake
of reﬁned carbohydrates,
excessive alcohol intake
Drugs Diuretics, cyclosporine,
glucocorticoids,
amiodarone
Oral estrogens,
glucocorticoids, bile acid
sequestrants,
protease inhibitors,
retinoic acid, anabolic
steroids, sirolimus,
raloxifene, tamoxifen,
beta blockers
(not carvedilol), thiazides
Diseases Biliary obstruction,
nephrotic syndrome
Nephrotic syndrome,
chronic renal failure,
lipodystrophies
Disorders and
altered states
of metabolism
Hypothyroidism,
obesity, pregnancy*
Diabetes (poorly controlled),
hypothyroidism, obesity;
pregnancy*
Adapted with permission from Stone et al (80).
*Cholesterol and triglycerides rise progressively throughout pregnancy (80); treatment with
statins, niacin, and ezetimibe are contraindicated during pregnancy and lactation.
LDL-C indicates low-density lipoprotein cholesterol.
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2903in persons >75 years of age with clinical ASCVD, according
to the potential for ASCVD risk-reduction beneﬁts, adverse
effects, drug–drug interactions, and consider patient prefer-
ences. The Expert Panel considers it reasonable to continue
statin therapy in persons >75 years of age who have clinical
ASCVD and are tolerating statin therapy.
The ﬂow diagram for the initiation and management of
statin therapy in individuals with clinical ASCVD is pro-
vided in Figure 3.
4.4. Primary Prevention in Individuals
‡21 Years of Age With LDL-C ‡190 mg/dL
This guideline recognizes that individuals 21 years of age
with primary, severe elevations of LDL-C (190 mg/dL)
have a high lifetime risk for ASCVD events. This is due to
their lifetime exposure to markedly elevated LDL-C
levels arising from genetic causes. Thus, at age 21, these
individuals should receive statin therapy if they have
not already been diagnosed and treated before this
age. Although in most clinical trials individuals with
LDL-C 190 mg/dL were not included because of their
need for treatment, extensive evidence shows that each 39-
mg/dL reduction in LDL-C by statin therapy reduces
ASCVD risk by about 20%. Patients with primary elevations
of LDL-C 190 mg/dL require even more substantial re-
ductions in their LDL-C levels and intensive management
Figure 4. Initiating Statin Therapy in Individuals Without Clinical ASCVD
Colors correspond to the Classes of Recommendation in Table 1.
*Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level 220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a
secondary etiology. If nonfasting triglycerides are 500 mg/dL, a fasting lipid panel is required.
yThe Pooled Cohort Equations can be used to estimate 10-year ASCVD risk in individuals with and without diabetes.
A downloadable spreadsheet enabling estimation of 10-year and lifetime risk for ASCVD and a Web-based calculator are available at http://my.americanheart.org/cvriskcalculator
and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx.
zFor those in whom a risk assessment is uncertain, consider factors such as primary LDL-C 160 mg/dL or other evidence of genetic hyperlipidemias; family history of
premature ASCVD with onset <55 years of age in a ﬁrst-degree male relative or <65 years of age in a ﬁrst-degree female relative, high-sensitivity C-reactive protein 2 mg/L;
CAC 300 Agatston units or 75th percentile for age, sex, and ethnicity (for additional information, see http://www.mesa-nhlbi.org/CACReference.aspx); ABI <0.9; or lifetime
risk of ASCVD. Additional factors that may aid in individual risk assessment could be identiﬁed in the future.
x1) Potential ASCVD risk-reduction beneﬁts. The absolute reduction in ASCVD events from moderate- or high-intensity statin therapy can be approximated by multiplying the
estimated 10-year ASCVD risk by the anticipated relative-risk reduction from the intensity of statin initiated (w30% for moderate-intensity statin orw45% for high-intensity statin
therapy). The net ASCVD risk-reduction beneﬁt is estimated from the number of potential ASCVD events prevented with a statin, compared to the number of potential excess
adverse effects. 2) Potential adverse effects. The excess risk of diabetes is the main consideration inw0.1 excess cases per 100 individuals treated with a moderate-intensity
statin for 1 year and w0.3 excess cases per 100 individuals treated with a high-intensity statin for 1 year. In RCTs, both statin-treated and placebo-treated participants expe-
rienced the same rate of muscle symptoms. The actual rate of statin-related muscle symptoms in the clinical population is unclear. Muscle symptoms attributed to statin therapy
should be evaluated (see Table 8, Safety Recommendation 8).
ABI indicates ankle-brachial index; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CK, creatine kinase; FH, familial
hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; RCT, randomized controlled trial; and ULN, upper limit of normal.
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Table 7. Rationale for the Expert Panel Approach to
Primary-Prevention Guidelines
1. Cholesterol-lowering medications, particularly statins, are efﬁcacious and
effective for reducing risk of initial cardiovascular events.
2. Statins are associated with similar relative risk reductions for cardiovas-
cular events across the majority of primary-prevention patient groups
studied.*
3. The extent of relative risk reduction for ASCVD is proportional to the degree
of LDL-C lowering observed on statin therapy. Therefore, more intensive
statin therapy could reduce risk more than moderate- or lower-intensity
statin therapy.
4. According to consistent ﬁndings, the absolute beneﬁt in ASCVD risk
reduction is proportional to the baseline risk of the patient group or indi-
vidual and to the intensity of statin therapy.
5. Patients or groups at higher baseline absolute risk, therefore, will derive
greater absolute beneﬁt from initiation of statin therapy over a period of
5 to 10 years.
6. The absolute risk for adverse outcomes, including a small excess in cases
of newly diagnosed diabetes, also appears to be proportional to the in-
tensity of statin therapy. However, the adverse outcome of incident (or
earlier diagnosis of) diabetes must be weighed in the context of the
potentially fatal or debilitating occurrence of MI or stroke that could be
prevented by statin therapy.
7. The Expert Panel emphasizes that the occurrence of a major ASCVD event
(MI or stroke) represents a much greater harm to health status than does
an increase in blood glucose leading to a diagnosis of diabetes. The net
absolute beneﬁt of statin therapy can be considered as a comparison of the
absolute risk reduction for ASCVD with the absolute excess risks, including
that for diabetes. Beneﬁt also could be understood as a comparison of the
number of statin-treated patients that would result in the prevention of 1
case of major ASCVD (NNT) with the number of statin-treated patients that
would result in 1 excess case of diabetes (NNH).
8. Because the absolute beneﬁt in terms of ASCVD risk reduction depends on
the baseline absolute risk for ASCVD, the absolute beneﬁt from initiation of
statin therapy is lower and would approach the risk for adverse effects in
patients with lower baseline levels of predicted ASCVD risk.
9. Available RCT evidence indicates a clear net absolute beneﬁt of initiation of
moderate-to-intensive statin therapy at a baseline estimated 10-year
ASCVD risk of 7.5%.
10.Available RCT evidence indicates that when baseline ASCVD risk is 5.0%
to <7.5%, there is still net absolute beneﬁt with moderate-intensity statin
therapy. However, the tradeoffs between the ASCVD risk-reduction beneﬁt
and adverse effects are less clear. Thus, a clinician-patient discussion is
even more important for individuals with this range of ASCVD risk. The net
beneﬁt of high-intensity statin therapy may be marginal in such individuals.
Conclusion
On the basis of the above tenets and its review of the evidence, this
guideline recommends initiation of moderate or intensive statin therapy for
patients who are eligible for primary ASCVD prevention and have a
predicted 10-year “hard” ASCVD risk of 7.5%. This guideline recommends
that initiation of moderate-intensity statin therapy be considered for
patients with predicted 10-year “hard” ASCVD risk of 5.0% to <7.5%.
*Available evidence suggests that initiation of statin therapy might not achieve a signiﬁcant
reduction of CVD risk in patients with higher classes of NYHA heart failure or who are receiving
maintenance hemodialysis.
ASCVD indicates atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL-C,
low-density lipoprotein cholesterol; MI, myocardial infarction; NNH, number needed to harm;
NNT, number needed to treat; NYHA, New York Heart Association; and RCT, randomized
controlled trial.
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2905of other risk factors to reduce their ASCVD event rates.
Therefore, it is reasonable to use high-intensity statin ther-
apy to achieve at least a 50% reduction. It is recognized that
maximal statin therapy might not be adequate to lower
LDL-C sufﬁciently to reduce ASCVD event risk in in-
dividuals with primary severe elevations of LDL-C. In
addition to a maximally tolerated dose of statin, nonstatin
cholesterol-lowering medications are often needed to lower
LDL-C to acceptable levels in these individuals. Because
the hypercholesterolemia in these high-risk individuals is
often genetically determined, family screening is especially
important in this group to identify additional family mem-
berswhowould beneﬁt from assessment and early treatment.
Secondary causes of severe elevations of LDL-C 190
mg/dL and triglycerides 500 mg/dL often contribute to
the magnitude of the hyperlipidemia and should be eval-
uated and treated appropriately. For guidance, we note that
in a lipid specialty clinic, the most frequently encountered
secondary conditions were excessive alcohol intake, un-
controlled diabetes, and overt albuminuria (79). Table 6
focuses on secondary causes of hyperlipidemia most likely
encountered in clinical practice (80). Management of in-
dividuals with fasting triglycerides 500 mg/dL has been
addressed in an AHA statement (45).
The ﬂow diagram for the initiation and management of
statin therapy in individuals with LDL-C 190 mg/dL is
provided in Figure 4.
4.5. Primary Prevention in
Individuals With Diabetes
A high level of evidence supports the use of moderate-
intensity statin therapy in persons with diabetes who are
40 to 75 years of age. The only trial of high-intensity statin
therapy in primary prevention was performed in a popu-
lation without diabetes. However, a high level of evidence
existed for event reduction with statin therapy in in-
dividuals with a 7.5% estimated 10-year ASCVD risk
(Section 4.6) who did not have diabetes to recommend
high-intensity statin therapy preferentially for individuals
with diabetes and a 7.5% estimated 10-year ASCVD risk
(Section 4.7). This consideration for those with diabetes
who are 40 to 75 years of age recognizes that these in-
dividuals are at substantially increased lifetime risk for
ASCVD events and death. Moreover, individuals with
diabetes experience greater morbidity and worse survival
after the onset of clinical ASCVD. In persons with dia-
betes who are <40 years of age or >75 years of age, or
whose LDL-C is <70 mg/dL, statin therapy should be
individualized on the basis of considerations of ASCVD
risk-reduction beneﬁts, the potential for adverse effects and
drug–drug interactions, and patient preferences (Figure 4).
4.6. Primary Prevention in Individuals Without
Diabetes and With LDL-C 70 to 189 mg/dL
In individuals 40 to 75 years of age with LDL-C 70 to
189 mg/dL who do not have clinical ASCVD or diabetes,
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2906initiation of statin therapy based on estimated 10-year
ASCVD risk is recommended, regardless of sex, race, or
ethnicity (Section 4.7). Point estimates of statin-associated
reductions in the relative risk of ASCVD in primary pre-
vention are similar for both women and men. There also is
no evidence that the ASCVD risk-reduction beneﬁt or
adverse-effect proﬁles differ by race.
To better identify those individuals without ASCVD
who would most beneﬁt from statin therapy to reduce
ASCVD risk, data were used from the 3 exclusively
primary-prevention RCTs that included individuals with
LDL-C levels <190 mg/dL, almost all of whom had
LDL-C levels 70 mg/dL (17,18,49). From these trials,
an estimate of the expected 10-year ASCVD event rates
was derived from the placebo groups. The rates of excess
adverse events in the statin treatment groups were obtained
from meta-analyses of statin RCTs. A high level of evi-
dence for an ASCVD risk-reduction beneﬁt from initia-
tion of moderate- or high-intensity statin therapy in
individuals 40 to 75 years of age with 7.5% estimated 10-
year ASCVD risk was found (Section 4.7). The reduction
in ASCVD risk clearly outweighs the potential for adverse
effects (Table 7). Thus, it is recommended that individuals
40 to 75 years of age, who are not already candidates for
statin therapy on the basis of the presence of clinical
ASCVD, diabetes, or LDL-C 190 mg/dL, receive statin
therapy if they have a 7.5% estimated 10-year risk for
ASCVD and LDL-C 70 to 189 mg/dL. Although only 1
exclusively primary-prevention RCT included individuals
with LDL-C 70 to <100 mg/dL, the Cholesterol Treat-
ment Trialists 2010 meta-analysis found a relative reduc-
tion in ASCVD events of similar magnitude across the
spectrum of LDL-C levels 70 mg/dL (20). Given that
the relative risk reduction is similar across the range of
LDL-C 70 to 189 mg/dL, the absolute beneﬁt of statin
therapy in primary prevention is determined by the global
risk estimate using all the risk factor information and is
reﬂected in the estimated 10-year ASCVD risk.
A conservative estimate of adverse events includes excess
cases of new-onset diabetes and rare cases of myopathy
and hemorrhagic stroke. The rate of excess diabetes varies
by statin intensity. For moderate-intensity statins, approxi-
mately 0.1 excess case of diabetes per 100 statin-treated
individuals per year has been observed, and for high-
intensity statins, approximately 0.3 excess case of diabetes
per 100 statin-treated individuals per year has been observed
(52,81). The long-term adverse effects of statin-associated
cases of diabetes over a 10-year period are unclear and are
unlikely to be equivalent to an MI, stroke, or ASCVD
death. Myopathy (w0.01 excess case per 100) and hemor-
rhagic stroke (w0.01 excess case per 100) make minimal
contributions to excess risk from statin therapy (13).
Although a similar level of evidence of a reduction in
ASCVD events from moderate- and high-intensity statin
therapy is present for those with a 5% to <7.5% estimated
10-year ASCVD risk, the potential for adverse effects mayoutweigh the potential for ASCVD risk-reduction beneﬁt
when high-intensity statin therapy is used in this risk group.
However, for moderate-intensity statin therapy, the ASCVD
risk reduction clearly exceeds the potential for adverse effects.
Before initiating statin therapy for the primary preven-
tion of ASCVD in adults with 7.5% or 5% to <7.5%
estimated 10-year ASCVD risk, it is reasonable for clini-
cians and patients to engage in a discussion of the proposed
therapy. This discussion should include the potential for
ASCVD beneﬁt, the potential for adverse effects and
drug–drug interactions, and consideration of patient pref-
erences for treatment.
No primary-prevention RCT data were available for
individuals 21 to 39 years of age, and few data were
available for individuals >75 years of age. Additionally, in
individuals 40 to 75 years of age with <5% estimated 10-
year ASCVD risk, the net beneﬁt from statin therapy over
a 10-year period may be small. Therefore, in adults with
LDL-C <190 mg/dL who are not otherwise identiﬁed in
a statin beneﬁt group or for whom a risk-based treatment
decision is uncertain after quantitative risk assessment,
clinician knowledge, experience, and skill (“the art of
medicine”) and patient preferences all contribute to the
decision to initiate statin therapy (82). Before initiation of
statin therapy, the clinician-patient discussion should
include consideration of the potential for ASCVD risk-
reduction beneﬁts, adverse effects, and drug–drug in-
teractions. Additional factors may also be considered to
inform treatment decision making in selected individuals.
Factors that can contribute to assessment of ASCVD risk
include primary LDL-C 160 mg/dL or other evidence of
genetic hyperlipidemias; family history of premature
ASCVD with onset <55 years of age in a ﬁrst-degree male
relative or <65 years of age in a ﬁrst-degree female relative;
high-sensitivity C-reactive protein 2 mg/L, coronary
artery calcium score 300 Agatston units or 75th
percentile for age, sex, and ethnicity (for additional infor-
mation, see http://www.mesa-nhlbi.org/CACReference.aspx);
ankle-brachial index <0.9; or elevated lifetime risk of
ASCVD. Additional factors that might aid in individual
risk assessment could be identiﬁed in the future.
For an individual <40 years of age, the 10-year horizon
might not be optimal for predicting lifetime risk of
ASCVD (see 2013 ACC/AHA Guideline on the
Assessment of Cardiovascular Risk) (11). Future RCTs
will be needed to determine the optimal age at which to
initiate statin therapy to reduce ASCVD risk, as well as to
determine the optimum duration of statin therapy.
4.7. Risk Assessment in Primary Prevention
To estimate more closely the total burden of ASCVD, this
guideline recommends a comprehensive assessment of the
estimated 10-year risk for an ASCVD event that includes
both CHD and stroke. This is in contrast to the use of an
estimated 10-year risk for hard CHD (deﬁned as nonfatal
MI and CHD death) (83).
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Cohort Risk Assessment Equations developed by the Risk
Assessment Work Group to estimate the 10-year ASCVD
risk (deﬁned as ﬁrst-occurrence nonfatal and fatal MI and
nonfatal and fatal stroke) for the identiﬁcation of candi-
dates for statin therapy (see http://my.americanheart.org/
cvriskcalculator and http://www.cardiosource.org/en/
Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/2013-Prevention-Guideline-Tools.aspx for risk
calculator). These equations should be used to predict
stroke as well as CHD events in non-Hispanic, Caucasian,
and African-American women and men 40 to 79 years of
age with or without diabetes who have LDL-C levels 70 to
189 mg/dL and are not receiving statin therapy. A more
complete discussion of risk assessment is provided in the
Full Panel Report Supplement.
This guideline does not require speciﬁc risk factor
counting for risk assessment or the use of RCT risk factor
inclusion criteria to determine statin eligibility. Rather, a
global ASCVD risk assessment to guide initiation of statin
therapy was chosen for several important reasons (see
rationale in Table 7 and further discussion in Section 7.3 of
the Full Panel Report Supplement): 1) The Cholesterol
Treatment Trialists individual-level meta-analyses were
used to evaluate the effect of statins in various important
patient subgroups, including risk factor cutpoints used for
RCT eligibility. The Expert Panel found that statin ther-
apy reduces ASCVD events regardless of risk factor
characteristics in both primary and secondary prevention.
Therefore, the rationale for using ﬁxed cutpoints to
determine whether statin therapy should be used is refuted
by a consideration of the total body of evidence. 2) Use of
absolute ASCVD risk facilitates a quantitative assessment
of the potential for an ASCVD risk-reduction beneﬁt as
compared with the potential for adverse effects. 3) Use of
an RCT eligibility criteria–based approach results in failure
to identify a substantial proportion of higher-risk in-
dividuals who could beneﬁt from statin therapy and over-
identiﬁcation of very-low-risk individuals who might not
experience a net beneﬁt from statin therapy over a 10-year
period.
4.8. Heart Failure and Hemodialysis
No recommendation was made with regard to the initia-
tion or continuation of statin therapy in 2 speciﬁc groups:
1) individuals with New York Heart Association class II–
IV heart failure, and 2) individuals undergoing mainte-
nance hemodialysis. In the 4 RCTs reviewed that specif-
ically addressed statin treatment in these groups, there
were individuals with and without heart disease (84–87).
Although statin therapy did not reduce ASCVD events in
2 RCTs for each condition (84–87), there was insufﬁcient
information on which to base recommendations for or
against statin treatment. Future research may identify
subgroups of patients with these conditions that may
beneﬁt from statin therapy. In individuals with theseconditions, the potential for ASCVD risk-reduction ben-
eﬁts, adverse effects, and drug–drug interactions, along
with other cautions and contraindications to statin therapy
and choice of statin dose, must also be considered by the
treating clinician.5. Safety: Recommendations
See safety recommendations for statins (Table 8) and
nonstatin drugs (Table 9).
RCT data were also used to examine the safety of lipid
medications. From the statin RCTs and meta-analyses,
patient characteristics and monitoring strategies were
identiﬁed that should enhance the safe use of high- and
moderate-intensity statin therapy. Patient characteristics
that may inﬂuence statin safety include but are not limited
to: multiple or serious comorbidities, including impaired
renal or hepatic function; a history of previous statin
intolerance or muscle disorders; concomitant use of drugs
affecting statin metabolism; a history of hemorrhagic
stroke; and age >75 years. Asian ancestry may also inﬂu-
ence the initial choice of statin intensity.
This guideline recommends against routine measure-
ment of creatine kinase in individuals receiving statin
therapy. This measurement should be reserved for those
with muscle symptoms. However, measurement of a base-
line creatine kinase may be useful in those at increased risk
of adverse muscle events. Such individuals include those
with a personal or family history of statin intolerance or
muscle disease, clinical presentation, or concomitant drug
therapy that might increase the likelihood of myopathy.
Expert recommendations are also provided for managing
muscle symptoms while a patient is on statin therapy.
These useful management suggestions were derived from
other clinical trial data and clinical experience to enhance
the safety and tolerability of statin therapy. Consistent with
the protocols of the RCTs, patients should be asked at each
visit, both before and after initiation of statin therapy,
about muscle symptoms such as muscle weakness or fa-
tigue, aching, pain, tenderness, cramps, or stiffness. The
recommended approach for management of muscle
symptoms is described in Table 8, Recommendation 8.
This guideline recommends that baseline measurement
of transaminase (alanine transaminase; ALT) levels should
be performed before initiation of statin therapy. This
approach was taken in the RCTs reviewed for this report.
There is no recommendation to monitor transaminase
(ALT) levels because ALT monitoring was performed in
the RCTs, and there was no signiﬁcant difference between
placebo groups and statin treatment groups in the rates of
ALT elevations. In addition, the U.S. Food and Drug
Administration has indicated that if the baseline hepatic
transaminases are normal, further hepatic monitoring is
not needed. During statin therapy, it is reasonable to
measure hepatic function if symptoms suggesting
Table 8. Statin Safety Recommendations
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Safety
1. To maximize the safety of statins, selection of the appropriate statin and dose
in men and nonpregnant/nonnursing women should be based on patient
characteristics, level of ASCVD* risk, and potential for adverse effects.
Moderate-intensity statin therapy should be used in individuals in whom
high-intensity statin therapy would otherwise be recommended when
characteristics predisposing them to statin-associated adverse effects are
present.
Characteristics predisposing individuals to statin adverse effects include but
are not limited to:
 Multiple or serious comorbidities, including impaired renal or hepatic
function.
 History of previous statin intolerance or muscle disorders.
 Unexplained ALT elevations 3 times ULN.
 Patient characteristics or concomitant use of drugs affecting statin
metabolism.
 Age >75 years.
Additional characteristics that could modify the decision to use higher statin
intensities might include but are not limited to:
 History of hemorrhagic stroke.
 Asian ancestry.
A (Strong) 46–55 I B
2a. CK should not be routinely measured in individuals receiving statin therapy. A (Strong) 45,49–51,54,55 III: No Beneﬁt A
2b. Baseline measurement of CK is reasonable for individuals believed to be at
increased risk for adverse muscle events because of a personal or family
history of statin intolerance or muscle disease, clinical presentation, or
concomitant drug therapy that might increase the risk of myopathy.
E (Expert Opinion) d IIa C
(88)
2c. During statin therapy, it is reasonable to measure CK in individuals with
muscle symptoms, including pain, tenderness, stiffness, cramping,
weakness, or generalized fatigue.
E (Expert Opinion) d IIa C
(88)
3a. Baseline measurement of hepatic transaminase levels (ALT) should be
performed before initiation of statin therapy.
B (Moderate) 46,52,53 Iy B
3b. During statin therapy, it is reasonable to measure hepatic function if
symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness,
loss of appetite, abdominal pain, dark-colored urine, or yellowing of the skin
or sclera).
E (Expert Opinion) d IIa C
(89)
4. Decreasing the statin dose may be considered when 2 consecutive values
of LDL-C levels are <40 mg/dL.
C (Weak) 45 IIb C
5. It may be harmful to initiate simvastatin at 80 mg daily or increase the
dose of simvastatin to 80 mg daily.
B (Moderate) 6,54 III: Harm A
(67,90)
6. Individuals receiving statin therapy should be evaluated for new-onset diabetes
according to the current diabetes screening guidelines (91). Those who
develop diabetes during statin therapy should be encouraged to adhere to
a heart-healthy dietary pattern, engage in physical activity, achieve and
maintain a healthy body weight, cease tobacco use, and continue statin
therapy to reduce their risk of ASCVD events.
B (Moderate) 44 Iz B
7. For individuals taking any dose of statins, it is reasonable to use caution in
individuals >75 years of age, as well as in individuals who are taking
concomitant medications that alter drug metabolism, taking multiple drugs,
or taking drugs for conditions that require complex medication regimens
(e.g., those who have undergone solid organ transplantation or are receiving
treatment for HIV). A review of the manufacturer’s prescribing information may
be useful before initiation of any cholesterol-lowering drug.
E (Expert Opinion) d IIa C
(16,64–70,
89,92–94)
Continued on the next page
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2908hepatotoxicity arise (e.g., unusual fatigue or weakness, loss
of appetite, abdominal pain, dark-colored urine, or yel-
lowing of the skin or sclera).
Decreasing the statin dose may be considered when
2 consecutive values of LDL-C are <40 mg/dL. This
recommendation was based on the approach taken in 2
RCTs. However, no data were identiﬁed that suggest an
excess of adverse events occurred when LDL-C levels were
below this level.Statins modestly increase the excess risk of type 2 dia-
betes in individuals with risk factors for diabetes.
The potential for an ASCVD risk-reduction beneﬁt out-
weighs the excess risk of diabetes in all but the lowest-risk
individuals (Section 4.5). All individuals receiving statins
should be counseled on healthy-lifestyle habits. In-
dividuals receiving statin therapy should be evaluated for
new-onset diabetes according to the current diabetes
screening guidelines (91). Those who develop diabetes
Table 8. Continued
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
8. It is reasonable to evaluate and treat muscle symptoms, including pain,
tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated
patients according to the following management algorithm:
 To avoid unnecessary discontinuation of statins, obtain a history of prior or
current muscle symptoms to establish a baseline before initiation of statin
therapy.
 If unexplained severe muscle symptoms or fatigue develop during statin
therapy, promptly discontinue the statin and address the possibility of
rhabdomyolysis by evaluating CK and creatinine and performing urinalysis
for myoglobinuria.
 If mild to moderate muscle symptoms develop during statin therapy:
– Discontinue the statin until the symptoms can be evaluated.
– Evaluate the patient for other conditions that might increase the risk for
muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic func-
tion, rheumatologic disorders such as polymyalgia rheumatica, steroid
myopathy, vitamin D deﬁciency, or primary muscle diseases).
– If muscle symptoms resolve, and if no contraindication exists, give the
patient the original or a lower dose of the same statin to establish a
causal relationship between the muscle symptoms and statin therapy.
– If a causal relationship exists, discontinue the original statin. Once
muscle symptoms resolve, use a low dose of a different statin.
– Once a low dose of a statin is tolerated, gradually increase the dose as
tolerated.
– If, after 2 months without statin treatment, muscle symptoms or
elevated CK levels do not resolve completely, consider other causes of
muscle symptoms listed above.
– If persistent muscle symptoms are determined to arise from a condition
unrelated to statin therapy, or if the predisposing condition has been
treated, resume statin therapy at the original dose.
E (Expert Opinion) d IIa B
(15,88,96–98)
9. For individuals presenting with a confusional state or memory impairment
while on statin therapy, it may be reasonable to evaluate the patient for
nonstatin causes, such as exposure to other drugs, as well as for systemic and
neuropsychiatric causes, in addition to the possibility of adverse effects
associated with statin drug therapy.
E (Expert Opinion) d IIb C
(38,89,99,100)
*Based on the presence of clinical ASCVD, diabetes, LDL-C 190 mg/dL, or level of estimated 10-year ASCVD risk.
yIndividuals with elevated ALT levels (usually>1.5 or 2 times ULN) were excluded from RCT participation. Unexplained ALT3 times ULN is a contraindication to statin therapy as listed in manufacturer’s
prescribing information.
zStatin use is associated with a very modest excess risk of new-onset diabetes in RCTs and meta-analyses of RCTs (i.e.,w0.1 excess cases per 100 individuals treated for 1 year with moderate-intensity
statin therapy andw0.3 excess cases per 100 individuals treated for 1 year with high-intensity statin therapy. The increased risk of new-onset diabetes appears to be conﬁned to those with risk factors
for diabetes. These individuals are also at higher risk of ASCVD because of these risk factors. Therefore, if a statin-treated individual develops diabetes as detected by current diabetes screening
guidelines, he or she should be counseled to adhere to a heart-healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin
therapy to reduce the risk of ASCVD events.
ACC indicates American College of Cardiology; AHA, American Heart Association; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CK, creatine kinase; COR, Class of
Recommendation; NHLBI, National Heart, Lung, and Blood Institute; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; RCTs, randomized controlled trials; ULN, upper limit of normal;
and d, not applicable.
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2909during statin therapy should be encouraged to adhere to a
heart-healthy dietary pattern, engage in physical activity,
achieve and maintain a healthy body weight, cease tobacco
use, and continue statin therapy to reduce their risk of
ASCVD events.
Statins are listed as pregnancy category X and should
not be used in women of childbearing potential unless
these women are using effective contraception and are not
nursing.
For individuals taking any dose of statins, it is reason-
able to use caution in individuals >75 years of age, as well
as in individuals who are taking concomitant medications
that alter drug metabolism, taking multiple drugs, or
taking drugs for conditions that require complex medi-
cation regimens (e.g., those who have undergone solidorgan transplantation or are receiving treatment for HIV).
A review of the manufacturer’s prescribing information
might be useful before initiation of any cholesterol-
lowering drug, because RCTs considered deﬁned pop-
ulations and many patients in everyday practice would not
qualify for clinical trials. Thus, clinicians should also
consult other sources of safety data, such as pharmacists,
drug information centers, and manufacturers’ prescribing
information on a regular basis for up-to-date guidance
about lipid medications and medication interactions.
Statins used in combination with other cholesterol-
lowering drug therapies might require more intensive
monitoring. The safety of nonstatin agents was reviewed,
and that information is included in Table 9 and the Full
Panel Report Supplement. Warnings about the use of
Table 9. Nonstatin Safety Recommendations
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Safety of Niacin
1. Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c,
and uric acid should be obtained before initiation of niacin, and again during
up-titration to a maintenance dose and every 6 months thereafter.
B (Moderate) 77 I B
2. Niacin should not be used if:
 Hepatic transaminase elevations are higher than 2 to 3 times ULN. A (Strong) 79 III: Harm B
 Persistent severe cutaneous symptoms, persistent hyperglycemia, acute
gout, or unexplained abdominal pain or gastrointestinal symptoms occur.
B (Moderate) 78,79 III: Harm B
 New-onset atrial ﬁbrillation or weight loss occurs. C (Weak) 80 III: Harm B
3. In individuals with adverse effects from niacin, the potential for ASCVD
beneﬁts and the potential for adverse effects should be reconsidered before
reinitiation of niacin therapy.
E (Expert) d I B
(9,101–104)
4. To reduce the frequency and severity of adverse cutaneous symptoms, it is
reasonable to:
 Start niacin at a low dose and titrate to a higher dose over a period of
weeks as tolerated.
 Take niacin with food or premedicate with aspirin 325 mg 30 minutes
before niacin dosing to alleviate ﬂushing symptoms.
 If an extended-release preparation is used, increase the dose of extended-
release niacin from 500 mg to a maximum of 2,000 mg/day over 4 to
8 weeks, with the dose of extended-release niacin increasing not more
than weekly.
 If immediate-release niacin is chosen, start at a dose of 100 mg 3 times
daily and up-titrate to 3 g/day, divided into 2 or 3 doses.
E (Expert) d IIa C
(9,101–104)
Safety of BAS
1. BAS should not be used in individuals with baseline fasting triglyceride
levels 300 mg/dL or type III hyperlipoproteinemia, because severe
triglyceride elevations might occur. (A fasting lipid panel should be obtained
before BAS is initiated, 3 months after initiation, and every 6 to 12 months
thereafter.)
C (Weak) 60 III: Harm B
2. It is reasonable to use BAS with caution if baseline triglyceride levels are
250 to 299 mg/dL, and evaluate a fasting lipid panel in 4 to 6 weeks after
initiation. Discontinue the BAS if triglycerides exceed 400 mg/dL.
E (Expert) d IIa C
(105)
Safety of Cholesterol-Absorption Inhibitors
1. It is reasonable to obtain baseline hepatic transaminases before initiation of
ezetimibe. When ezetimibe is coadministered with a statin, monitor trans-
aminase levels as clinically indicated, and discontinue ezetimibe if persistent
ALT elevations 3 times ULN occur.
C (Weak) 61–64 IIa B
Safety of Fibrates
1. Gemﬁbrozil should not be initiated in patients on statin therapy because of an
increased risk for muscle symptoms and rhabdomyolysis.
B (Moderate) 46 III: Harm B
2. Fenoﬁbrate may be considered concomitantly with a low- or moderate-
intensity statin only if the beneﬁts from ASCVD risk reduction or triglyceride
lowering when triglycerides are 500 mg/dL are judged to outweigh the
potential risk for adverse effects.
E (Expert) d IIb C
(14)
3. Renal status should be evaluated before fenoﬁbrate initiation, within 3
months after initiation, and every 6 months thereafter. Assess renal safety
with both a serum creatinine level and an eGFR based on creatinine.
B (Moderate) 66,67 I B
 Fenoﬁbrate should not be used if moderate or severe renal impairment,
deﬁned as eGFR <30 mL/min per 1.73 m2, is present.
 If eGFR is between 30 and 59 mL/min per 1.73 m2, the dose of fenoﬁbrate
should not exceed 54 mg/day.*
 If, during follow-up, the eGFR decreases persistently to 30 mL/min per
1.73 m2, fenoﬁbrate should be discontinued.
III: Harm B
Safety of Omega-3 Fatty Acids
1. If EPA and/or DHA are used for the management of severe
hypertriglyceridemia, deﬁned as triglycerides 500 mg/dL, it is reasonable to
evaluate the patient for gastrointestinal disturbances, skin changes, and
bleeding.
C (Weak) 70 IIa B
*Consult the manufacturer’s prescribing information as there are several forms of fenoﬁbrate available.
ACC indicates American College of Cardiology; AHA, American Heart Association; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; BAS, bile acid sequestrants; COR, Class of
Recommendation; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; eGFR, estimated glomerular ﬁltration rate; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; ULN,
upper limit of normal; and d, not applicable.
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Table 10. Recommendations for Monitoring, Optimizing, and Addressing Insufﬁcient Response to Statin Therapy
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Monitoring Statin Therapy
1. Adherence to medication and lifestyle, therapeutic response to statin
therapy, and safety should be regularly assessed. This should also
include a fasting lipid panel performed within 4–12 weeks after initiation
or dose adjustment, and every 3–12 months thereafter. Other safety
measurements should be measured as clinically indicated.
A (Strong) 45 I A
Optimizing Statin Therapy
1. The maximum tolerated intensity of statin should be used in individuals for
whom a high- or moderate-intensity statin is recommended but not tolerated.
B (Moderate) 25,26,27,45 I* B
Insufﬁcient Response to Statin Therapy
1. In individuals who have a less-than-anticipated therapeutic response or are
intolerant of the recommended intensity of statin therapy, the following should
be performed:
 Reinforce medication adherence.
 Reinforce adherence to intensive lifestyle changes.
 Exclude secondary causes of hyperlipidemia.
A (Strong) 45 I A
2. It is reasonable to use the following as indicators of anticipated therapeutic
response to the recommended intensity of statin therapy. Focus is on the
intensity of the statin therapy. As an aid to monitoring:
 High-intensity statin therapyy generally results in an average LDL-C
reduction of 50% from the untreated baseline.
 Moderate-intensity statin therapy generally results in an average
LDL-C reduction of 30% to <50% from the untreated baseline.
 LDL-C levels and percents reduction are to be used only to assess
response to therapy and adherence. They are not to be used as
performance standards.
E (Expert Opinion) d IIa B
(46–48,78,
106,107)
3. In individuals at higher ASCVD risk receiving the maximum tolerated
intensity of statin therapy who continue to have a less-than-anticipated
therapeutic response, addition of nonstatin cholesterol-lowering drug(s) may
be considered if the ASCVD risk-reduction beneﬁts outweigh the potential for
adverse effects.
Higher-risk individuals include:
 Individuals with clinical ASCVDz <75 years of age.
 Individuals with baseline LDL-C 190 mg/dL.
 Individuals 40–75 years of age with diabetes.
Preference should be given to nonstatin cholesterol-lowering drugs shown to
reduce ASCVD events in RCTs.
E (Expert Opinion) d IIb C
(9,14,108–110)
4. In individuals who are candidates for statin treatment but are completely
statin intolerant, it is reasonable to use nonstatin cholesterol-lowering drugs
that have been shown to reduce ASCVD events in RCTs if the ASCVD risk-
reduction beneﬁts outweigh the potential for adverse effects.
E (Expert Opinion) d IIa B
(88,101,111–116)
*Several RCTs found that low-intensity and low-moderate–intensity statin therapy reduced ASCVD events. In addition, the Cholesterol Treatment Trialists meta-analyses found that each 39-mg/dL
reduction in LDL-C reduces ASCVD risk by 22%. Therefore, the Panel considered that submaximal statin therapy should be used to reduce ASCVD risk in those unable to tolerate moderate- or high-
intensity statin therapy.
yIn those already on a statin, in whom baseline LDL-C is unknown, an LDL-C level <100 mg/dL was observed in most individuals receiving high-intensity statin therapy.
zClinical ASCVD includes acute coronary syndromes, or a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or
peripheral arterial disease presumed to be of atherosclerotic origin.
ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; COR, Class of Recommendation; LDL-C, low-density lipoprotein
cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; RCTs, randomized controlled trials; and d, not applicable.
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apply to nonstatins, and the manufacturer’s prescribing
information should be consulted.
6. Managing Statin Therapy:
Recommendations
See Table 10 for a summary of recommendations for
monitoring, optimizing, and addressing insufﬁcient
response to statin therapy.6.1. Monitoring Statin Therapy
A high level of RCT evidence supports the use of an
initial fasting lipid panel (total cholesterol, triglycerides,
HDL-C, and calculated LDL-C), followed by a second
lipid panel 4 to 12 weeks after initiation of statin therapy,
to determine a patient’s adherence. Thereafter, assess-
ments should be performed every 3 to 12 months as
clinically indicated. Adherence to both medication and
lifestyle regimens are required for ASCVD risk reduc-
tion. After statin therapy has been initiated, some
Figure 5. Statin Therapy: Monitoring Therapeutic Response and Adherence
Colors correspond to the Classes of Recommendation in Table 1.
*Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level220 mg/dL may indicate genetic hypercholesterolemia that requires further evaluation or a secondary
etiology. If nonfasting triglycerides are 500 mg/dL, a fasting lipid panel is required.
yIn those already on a statin, in whom baseline LDL-C is unknown, an LDL-C <100 mg/dL was observed in most individuals receiving high-intensity statin therapy in RCTs.
zSee Section 6.3.1.
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and RCTs, randomized clinical trials.
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2912individuals experience unacceptable adverse effects when
taking the recommended intensity of statin therapy.
Once the severity and association of adverse effects with
statin therapy has been established, and once factors
potentially contributing to statin intolerance are resolved,
the patient should be given lower doses of the same statin
or an alternative appropriate statin, until a statin and dose
that have no adverse effects have been identiﬁed (Table 8,
Recommendation 8).
See Figure 5 for a ﬂow diagram on monitoring statin
response for the initiation of nonstatin therapy.
6.2. Optimizing Statin Therapy
Although high-intensity statin therapy reduces ASCVD
events more than moderate-intensity statin therapy,
lower-intensity statin therapy has also been shown to
reduce ASCVD events, although to a lesser degree.
Therefore, individuals who merit guideline-recommended
statin therapy should be treated with the maximum-
appropriate intensity of a statin that does not cause
adverse effects.6.3. Insufﬁcient Response to Statin Therapy
6.3.1. Testing
The evidence is less clear with regard to the most appropriate
tests for determining whether an anticipated therapeutic
response to statin therapy has occurred on the maximally
tolerated dose. RCT evidence to support the use of speciﬁc
LDL-C or non–HDL-C targets was not identiﬁed. The
focus is on the intensity of the statin therapy, but as an aid to
monitoring response to therapy and adherence, it is reason-
able to use the following as indicators of anticipated thera-
peutic response to statin therapy:
 High-intensity statin therapy generally results in an
average LDL-C reduction of 50% from the un-
treated baseline.
 Moderate-intensity statin therapy generally results in
an average LDL-C reduction of 30% to <50% from
the untreated baseline.
 LDL-C levels and percent reduction are to be
used only to assess response to therapy and adherence.
They are not to be used as performance standards.
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2913In those already on a statin, in whom the baseline LDL-
C is unknown, an LDL-C <100 mg/dL was observed in
most individuals receiving high-intensity statin therapy in
RCTs.
However, there are many limitations of using LDL-C
<100mg/dL as a ﬁxed target. If amoderate- or low-intensity
statin results in an LDL-C level <100 mg/dL in a patient
with ASCVD, the evidence suggests that a high-intensity
statin, if tolerated, provides a greater reduction in ASCVD
events. Conversely, in those with LDL-C levels slightly
>100mg/dL on a high-intensity statin, some options such as
niacin might require down-titration of the statin intensity in
an effort to improve safety. This would result in a suboptimal
intensity of evidence-based statin therapy. Additional limi-
tations to usingLDL-C treatment targets are discussed in the
Full Panel Report Supplement.
No evidence was found that titration or combination-
drug therapy to achieve speciﬁc LDL-C or non–HDL-C
levels or percent reductions improved ASCVD outcomes.
Therefore, this guideline does not recommend their use as
performance measures.
The percent LDL-C reduction may not only indicate
adherence, but also may reﬂect biological variability in
the response to statin therapy. This acknowledges that some
individualsmayhave less than an average response.Attention
to adherence of statin and lifestyle therapy and evaluation
and treatment of secondary causes (Table 6) that might el-
evate LDL-C, may address less-than-anticipated responses
to a speciﬁc statin dosage.Whether the dose of statin therapy
should be increased on the basis of a less-than-anticipated
average response should be left to clinical judgment.
6.3.2. Nonstatins Added to Statins or
in Statin-Intolerant Individuals
Adherence to lifestyle changes and to statin therapy should
be reemphasized before the addition of a nonstatin drug is
considered (Figure 5). RCTs evaluating the ASCVD event
reductions from nonstatins used as monotherapy were
reviewed, as were RCTs evaluating the additional reduc-
tion in ASCVD events from nonstatin therapy added to
statin therapy. The Expert Panel could ﬁnd no data sup-
porting the routine use of nonstatin drugs combined with
statin therapy to further reduce ASCVD events. In addi-
tion, no RCTs that assessed ASCVD outcomes in statin-
intolerant patients were found.
Clinicians treating high-risk patients who have a less-
than-anticipated response to statins, who are unable to
tolerate a less-than-recommended intensity of a statin, or
who are completely statin intolerant, may consider the
addition of a nonstatin cholesterol-lowering therapy.
High-risk individuals include those with ASCVD, those
with LDL-C 190 mg/dL, and those with diabetes
40–75 years of age. In this situation, this guideline rec-
ommends clinicians preferentially prescribe drugs that
have been shown in RCTs to provide ASCVD risk-
reduction beneﬁts that outweigh the potential for adverseeffects and drug–drug interactions, and consider patient
preferences.
7. Selected Clinical and
Population Subgroups
7.1. Sex and Racial and Ethnic Subgroups
Because the RCT evidence shows that the absolute beneﬁt
of statin treatment is proportional to baseline ASCVD
risk, treatment decisions for women and racial and ethnic
subgroups should be based on the level of ASCVD risk.
This conclusion is a departure from previous approaches
that focused on LDL-C levels to guide treatment de-
cisions. Statin treatment based on estimated 10-year
ASCVD risk avoids the overtreatment of lower-risk
groups, such as younger, non-Hispanic white women
who, despite moderate elevations in LDL-C, are typically
not at signiﬁcantly increased risk for ASCVD in the next
10 years in the absence of substantial risk factor burden.
However, ignoring the increased ASCVD risk in African
American women and men might result in the under-
treatment of some individuals who are at signiﬁcantly
higher ASCVD risk at the same LDL-C level. Thus, this
guideline recommends statin therapy for individuals in
whom it is most likely to provide ASCVD risk reduction
on the basis of the estimated 10-year risk of ASCVD.
7.2. Individuals >75 Years of Age
Fewer people >75 years of age were enrolled in the statin
RCTs reviewed. RCT evidence does support the contin-
uation of statins beyond 75 years of age in persons who are
already taking and tolerating these drugs. A larger amount
of data supports the use of moderate-intensity statin
therapy for secondary prevention in individuals with clin-
ical ASCVD who are >75 years of age. However, the
limited information available did not clearly support
initiation of high-intensity statin therapy for secondary
prevention in individuals >75 years of age.
Few data were available to indicate an ASCVD event
reduction beneﬁt in primary prevention among individuals
>75 years of age who do not have clinical ASCVD.
Therefore, initiation of statins for primary prevention of
ASCVD in individuals >75 years of age requires consid-
eration of additional factors, including increasing comor-
bidities, safety considerations, and priorities of care. The
Pooled Cohort Equations can also provide information on
expected 10-year ASCVD risk for those 76 to 79 years of
age that may inform the treatment decision. These factors
may inﬂuence decisions about cholesterol-lowering drug
therapy, especially in the primary-prevention setting.
Accordingly, a discussion of the potential ASCVD risk-
reduction beneﬁts, risk of adverse effects, drug–drug in-
teractions, and consideration of patient preferences should
precede the initiation of statin therapy for primary pre-
vention in older individuals.
Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889–934
29148. Limitations
The evidence-based recommendations in this guideline
focus on patient groups who are well represented in RCTs
and/or are highly likely to have high-risk genetic condi-
tions, so the recommendations are designed to inform
rather than replace clinical judgment. However, there are
other patient groups for which a robust evidence base is
lacking but that may nevertheless include some persons for
whom statin treatment should be considered (after taking
patient preferences into account) on the basis of the po-
tential for ASCVD beneﬁts to exceed the risk of adverse
events and drug–drug interactions. Clinician judgment is
especially important for several patient groups for which
the RCT evidence is insufﬁcient for guiding clinical rec-
ommendations. These patient groups include younger
adults (<40 years of age) who have a low estimated 10-year
ASCVD risk but a high lifetime ASCVD risk based
on single strong factors or multiple risk factors. Other
groups include those with serious comorbidities and
increased ASCVD risk (e.g., individuals with HIV or
rheumatologic or inﬂammatory diseases, or who have un-
dergone a solid organ transplantation). This guideline
encourages clinicians to use clinical judgment in these
situations, weighing potential beneﬁts, adverse effects,
drug–drug interactions, and consider patient preferences.
Previous guidelines have taken less rigorous approaches
to identifying the evidence to support their recommen-
dations. In contrast, to minimize various sources of bias,
the present recommendations are based on data available
from RCTs and systematic reviews and meta-analyses of
RCTs that were graded as fair to good quality by an
independent contractor and were reviewed by the Expert
Panel, with the assistance of an independent methodolo-
gist. To avoid biases, evidence from post-hoc analyses of
included RCTs, from poor-quality RCTs, and from
observational studies was not considered. This approach
resulted in a comprehensive set of evidence-based clinical
recommendations for the treatment of blood cholesterol to
reduce ASCVD risk.9. Evidence Gaps and
Future Research Needs
After a systematic review of the literature, several research
priorities are suggested that address existing evidence gaps
and offer the greatest potential to inform and inﬂuence
clinical practice and reduce ASCVD morbidity and mor-
tality. High-priority research areas are:
1. Outcomes of RCTs to evaluate statins for the pri-
mary prevention of ASCVD in adults >75 years of
age.
2. Outcomes of RCTs to evaluate alternative treatment
strategies for ASCVD risk reduction. These RCTsmay compare titration to speciﬁc cholesterol or
apolipoprotein goals versus ﬁxed-dose statin therapy
in high-risk patients.
3. RCTs to determine whether submaximal statin
doses, combined with nonstatin therapies, reduce
ASCVD risk in statin-intolerant patients.
4. Evaluation of the incidence, pathophysiology, clin-
ical course, and clinical outcomes of new-onset
diabetes associated with statin therapy.
5. Outcomes of RCTs of new lipid-modifying agents to
determine the incremental ASCVD event-reduction
beneﬁts when added to evidence-based statin therapy.
Additional research recommendations are included in
the Full Panel Report Supplement.10. Conclusions
These recommendations arose from careful consideration
of an extensive body of higher-quality evidence derived
from RCTs and systematic reviews and meta-analyses of
RCTs. Rather than LDL-C or non–HDL-C targets, this
guideline used the intensity of statin therapy as the goal of
treatment. Through a rigorous process, 4 groups of in-
dividuals were identiﬁed for whom an extensive body of
RCT evidence demonstrated a reduction in ASCVD
events with a good margin of safety from moderate- or
high-intensity statin therapy:
Four Statin Beneﬁt Groups:
1. Individuals with clinical ASCVD
2. Individuals with primary elevations of LDL-C 190
mg/dL
3. Individuals 40 to 75 years of age with diabetes and
LDL-C 70 to 189 mg/dL without clinical ASCVD
4. Individuals without clinical ASCVD or diabetes
who are 40 to 75 years of age and have LDL-C 70 to
189 mg/dL and an estimated 10-year ASCVD risk of
7.5%. This requires a clinician-patient discussion.
Individuals in the last group can be identiﬁed by using
the Pooled Cohort Equations for ASCVD risk prediction
developed by the Risk Assessment Work Group. Lifestyle
counseling should occur at the initial and follow-up visits
as the foundation for statin therapy and may improve the
overall risk factor proﬁle.
Most importantly, our focus is on those individuals most
likely to beneﬁt from evidence-based statin therapy to
reduce ASCVD risk. Implementation of these ASCVD
risk-reduction guidelines will help to substantially address
the large burden of fatal and nonfatal ASCVD in the
United States. We realize that these guidelines represent a
change from previous guidelines, but clinicians have become
accustomed to change when that change is consistent with
the current evidence. Continued accumulation of quality
trial data will inform future cholesterol treatment guidelines.
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RWI ¼ relationships with industry and other entitiesAppendix 4. Evidence StatementsES No. Evidence Statement
Level of
Evidence
Recommendation(s)/
Section References
1 Data are not available regarding treatment or titration to a speciﬁc LDL-C
goal in adults with CHD/CVD. The Expert Panel found insufﬁcient
evidence to support setting LDL-C goals in CHD/CVD patients.
I Secondary Prevention Conclusion after reviewing 19 RCTs in CQ1 Evidence
Table:
4D (87), A–Z (117), ACCORD (14), ALLIANCE (118),
ASPEN (119), AURORA (84), CARE (73),
CORONA (85), GREACE (120), HATS (121), HPS
(16), IDEAL (47), LIPID (74), LIPS (122), MIRACL
(93), MUSHASHI-AMI (123), PROVE-IT (48),
SPARCL (78,107), TNT (46)
2 The Expert Panel did not identify any trials in adults with CHD/CVD
reporting mean or median on-treatment non–HDL-C levels in adults with
CHD/CVD.
Secondary Prevention N/A
3 LDL-C goals <130 mg/dL or <100 mg/dL in patients without CHD/CVD.
Randomized trial data are not available regarding dose titration to
achieve a speciﬁc LDL-C goal.
I Primary Prevention Conclusion after reviewing 6 RCTs included in CQ2:
AFCAPS (17), ASPEN (119), AURORA (84), CARDS
(75), JUPITER (49), MEGA (18)
4 There was insufﬁcient evidence in women without CHD/CVD to evaluate
the reduction in CVD risk with achieved LDL-C levels <130 mg/dL
or <100 mg/dL.
I Primary Prevention N/A
5 The Expert Panel did not identify any trials in adults without CHD/CVD
reporting on-treatment non–HDL-C levels in adults with CHD/CVD.
Primary Prevention N/A
6 In adults with CHD/CVD, ﬁxed high-intensity statin treatment (atorvastatin
40–80 mg) that achieved a mean LDL-C 67–79 mg/dL reduced the
RR for CHD/CVD events more than ﬁxed lower-dose statin treatment
that achieved a mean LDL-C 97–102 mg/dL. In these trials, the
mean LDL-C levels achieved differed by 23–30 mg/dL, or 22%–32%,
between the 2 groups. Simvastatin 80 mg did not decrease CVD
events compared with simvastatin 20–40 mg.
See Table 4 for deﬁnitions of high, moderate, and low intensity for statins.
Higher intensity ¼ atorvastatin 40–80 mg
Moderate intensity ¼ atorvastatin 10 mg, pravastatin 40 mg,
or simvastatin 20–40 mg
H Secondary Prevention Beneﬁt:
TNT (46), IDEAL (47), PROVE-IT (48)
Lower LDL-C reductions, no beneﬁt:
A–Z (117), ACCORD (14)
No difference in LDL-C between groups: (SEARCH
(124) not included in CQ1)
7 In adults with CHD/CVD who do not have Class II–IV heart failure, ﬁxed
high-intensity statin (atorvastatin 80 mg) or statin-niacin treatment that
achieved a mean LDL-C 72–79 mg/dL reduced the RR for CHD/CVD
events compared with placebo with a mean LDL-C 112–135 mg/dL.
In these trials, the mean LDL-C levels were reduced by 45–57 mg/dL
or by 45% (HATS [121]) to 53% (SPARCL [107]).
H Secondary Prevention SPARCL (107)
HATS (121)
MIRACL (93)
CORONA (85)–no beneﬁt
Continued on the next page
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8 In adults with CHD/CVD and diabetes, ﬁxed high-intensity statin treatment
(atorvastatin 80 mg) that achieved a mean LDL-C of 57–77 mg/dL
reduced the RR for CHD/CVD events more than ﬁxed lower-intensity
statin treatment that achieved a mean LDL-C of 81–99 mg/dL. In these
trials, the mean LDL-C levels achieved differed by 22–24 mg/dL,
or 22%–30%, between the 2 groups.
M to H Secondary Prevention
(diabetes subgroup
included)
TNT (46,94), PROVE-IT (48,125)
No diabetes subgroup publications found for MIRACL
(93) or IDEAL (47)
9 In adults 65 years of age with CHD/CVD, ﬁxed high-intensity statin
treatment (atorvastatin 80mg) that achieved a mean LDL-C of 72mg/dL
reduced CHD/CVD eventsmore than ﬁxed lower-intensity statin treatment
that achieved a mean LDL-C of 97 mg/dL. In this trial, the mean LDL-C
levels achieved differed by 25 mg/dL, or 26%, between the 2 groups. In
adults 65 years of age with a history of stroke or TIA, higher ﬁxed-dose
statin treatment that achieved a mean LDL-C of 72 mg/dL reduced CHD
events more than placebo, with a mean LDL-C of 129 mg/dL. In this trial,
themean LDL-C level was reduced by 61mg/dL, or 46%, from baseline in
those 65 years of age.
L Secondary Prevention (age
subgroups included)
TNT (46,126), SPARCL (107,127)
No publications by age included for:
PROVE-IT (48)
IDEAL (47)
HATS (121)
10 In adults with CHD/CVD and CKD (excluding hemodialysis), ﬁxed high-
intensity statin treatment (atorvastatin 80 mg) that achieved a mean
LDL-C of 79 mg/dL reduced CHD/CVD events more than ﬁxed lower-
dose statin treatment that achieved a mean LDL-C of 99 mg/dL. In this
trial, the mean LDL-C levels achieved differed by 20 mg/dL, or 20%
between the 2 groups.
L Secondary Prevention (CKD
subgroup included)
TNT (46,128)
TNT (46,129)
No publications included for CKD:
PROVE-IT (48)
IDEAL (47)
11 In adults with CHD or acute coronary syndromes, more intensive-dose
statin therapy reduced LDL-C to a greater degree (by 20 mg/dL or an
additional 20%) than less intensive-dose statin therapy or placebo and
produced a greater reduction in CVD events.
Each 1-mmol/L (38.7-mg/dL) reduction in LDL-C reduced the RR for CVD
events by approximately 28%.
See Table 4 for deﬁnitions of high-, moderate-, and low-intensity statin
therapy.
More intensive statin therapy ¼ atorvastatin 80 mg, simvastatin 80 mg.
Less intensive statin therapy ¼ atorvastatin 10 mg, pravastatin 40 mg,
or simvastatin 20–40 mg.
H Secondary Prevention CTT 2010 (20)ddata from 5 trials
TNT (46)
IDEAL (47)
PROVE-IT (48)
A–Z (117)
SEARCH (124) (not included in CQ1)
12 In trials of more intensive statin therapy (atorvastatin 80 mg, simvastatin
80 mg) compared with less intensive statin therapy (atorvastatin 10
mg, pravastatin 40 mg, or simvastatin 20–40 mg), women with CHD or
acute coronary syndromes experienced a similar (approximately 25%)
magnitude of relative CVD reduction as men (approximately 29%).
Women also experienced a similar magnitude of absolute risk
reduction as men.
H Secondary Prevention
(women included)
CTT 2010 (20)d5 trials
TNT (46)
IDEAL (47)
PROVE-IT (48)
A–Z (117)
SEARCH (124) (not included in CQ1)
13 In adults with and without CVD, in trials comparing more intensive to less
intensive statin therapy or statin therapy with placebo/control, the
relative CVD risk reduction was similar for those <65 years, 65 to 75,
or >75 years of age. There is less information to estimate the
magnitude of beneﬁt in those under age 45 or over age 75 years,
because fewer participants in these age groups were enrolled in clinical
trials. More intensive statin therapy did not appear to reduce CVD risk,
compared with less intensive statin therapy, in those with ASCVD and
age >75 years. Statin therapy, compared with control (most RCTs
evaluated moderate-intensity statin therapy), had a similar magnitude
of RR reduction in those >75 as in those 75 years of age with and
without ASCVD.
Statin therapy vs. control trials ¼ atorvastatin (A) 10–20 mg, ﬂuvastatin (F)
80 mg, lovastatin (L) 40–80 mg, pravastatin (P) 40 mg, rosuvastatin (R)
10–20 mg, simvastatin (S) 40 mg.
See Table 4 for the Expert Panel’s deﬁnitions for high-, moderate-, and low-
intensity statin therapy.
The Panel uses moderate intensity to refer to statin drugs and doses that
lower LDL-C by 30% to approximately 50%.
This dose refers to atorvastatin 10 mg, ﬂuvastatin 80 mg, lovastatin 40
mg, pravastatin 40 mg, rosuvastatin 10 mg, and simvastatin 40 mg.
H Primary Prevention,
Secondary Prevention
CTT 2010 (20)d26 trials
Included:
More vs. less statin
TNT (46)
IDEAL (47)
PROVE-IT (48)
A–Z (117)
SEARCH (124)
Statin vs. control (statin/dose, percent LDL-C
reduction)
4S (47) S20–40, –36%
WOSCOPS (72) P40, –22%
CARE (130) P40, –29%
AFCAPS/TexCAPS (17) L20-40, –24%
LIPID (74) P40, –27%
GISSI-P (86) P20, –9%
LIPS (122) F40 BID, –27%
HPS (16) S40, –38%
PROSPER (38) P40, –27%
ALLHAT-LLT (131) P40, –14%
ASCOT-LLA (132) A10, –31%
ALERT (133) F40, –20%
CARDS (75) A10, –38%
ALLIANCE (118)dNA
4D (87)dA20, –27%
ASPEN (119) A10, –34%
MEGA (18) P10–20, –17%
JUPITER (49) R20, –40%
GISSI-HF (86) R10, –30%
AURORA (84) R10, –38%
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14 In adults with CHD (including acute coronary syndromes, or a history of MI,
stable or unstable angina, coronary revascularization), statin therapy
reduced the RR for CVD events by approximately 21% per 1-mmol/L
(38.7-mg/dL) LDL-C reduction. This relationship was similar for more
intensive compared with less intensive statin therapy and for statin
therapy compared with placebo/control.
H Secondary Prevention CTT 2010 (20)d26 trialsdsee above
15 In adults with CVD other than CHD (including stroke, TIA presumed to be of
atherosclerotic origin, or peripheral arterial disease or
revascularization), statin therapy reduced the RR for CVD events by
approximately 19% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
This relationship was similar for more intensive compared with less
intensive statin therapy and for statin therapy compared with
placebo/control.
H Secondary Prevention CTT 2010 (20)d26 trials
16 In adults with diabetes and CHD or other CVD, moderate-dose statin
therapy reduced CVD events by approximately 20% per 1-mmol/L
(38.7-mg/dL) LDL-C reduction.
H Secondary Prevention
(diabetes subgroup
included)
CTT 2008 (134)d14 trials
17 In adults with and without CVD, statin therapy reduced CVD events in both
men and women.
H Primary Prevention,
Secondary Prevention
CTT 2010 (20)d26 trials
18 In adults with and without CVD, in trials comparing more* intensive with
less intensive statin therapy, or statin therapy with placebo/control,
there were no clinically important differences in the CVD risk reduction
between the subgroups listed below:
 Treated hypertension or all others
 Systolic blood pressure <140, 140 to <160, and 160 mm Hg
 Diastolic blood pressure <80, 80 to <90, and 90 mm Hg
 Body mass index <25, 25 to <30, and 30 kg/m2
 Current smoking and nonsmokers
GFR <60, 60 to <90, 90 mL/min per 1.73 m2)
 Post-MI
 Total cholesterol 5.2 (201 mg/dL), >5.2 to 6.5, >6.5
(251 mg/dL) mmol/L
 Triglycerides 1.4 (124 mg/dL), >1.4 to 2.0, >2.0 (177 mg/dL)
mmol/L
 HDL-C 1.0 (39 mg/dL), >1.0 to 1.3, >1.3 (50 mg/dL) mmol/L
H Primary Prevention,
Secondary Prevention
CTT 2010 (20)d26 trials
19 Inmore vs. less statin and statin vs. control trials combined, each 1-mmol/L
(38.7-mg/dL) reduction in LDL-C resulted in approximately 22%
reductions in CVD risk across baseline LDL-C levels [<2 mmol/L (77
mg/dL), 2 to <2.5 mmol/L (97 mg/dL), 2.5 to <3.0 mmol/L (116
mg/dL), 3.0 to <3.5 mmol/L (135 mg/dL), and 3.5 mmol/L, either
untreated or on statin therapy]. In the statin vs. placebo/control trials,
those with LDL-C <2 mmol/L may have experienced less beneﬁt than
those with higher LDL-C level.
M CTT 2010 (20)d26 trials
20 In adults, statins reduce the RR for CVD, CHD, and fatal CHD similarly in
those with or without hypertension. This beneﬁt applies across all levels
of baseline systolic and diastolic blood pressure and in those with
treated hypertension.
H Primary Prevention,
Secondary Prevention
CTT 2010 (20), Messerli AJC 2008 (135)
21 In adults with and without CVD who received more intensive compared
with less intensive statin therapy, or statin therapy compared with
placebo/control, the RR for ﬁrst stroke was reduced by approximately
16% per 1-mmol/L (38.7-mg/dL) LDL-C reduction, primarily because of
an approximately 21% reduction in the RR for ischemic stroke.
M to H Primary Prevention,
Secondary Prevention
CTT 2010 (20)d26 trials
22 In adults with and without CHD/CVD who received more intensive
compared with less intensive statin therapy, or statin therapy compared
with placebo/control:
 The RR for major coronary events was reduced by approximately
24% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
 The RR for nonfatal myocardial infarction was reduced by approxi-
mately 27% per 1-mmol/L LDL-C reduction.
 Total mortality was reduced by approximately 10% per 1-mmol/L
(38.7-mg/dL) LDL-C reduction, primarily because of a 16%
reduction in the risk for cardiac death.
 The risk for CVD mortality was reduced by approximately 14% per
1-mmol/L (38-mg/dL) LDL-C reduction, primarily because of a 16%
reduction in the risk for cardiac death.
H Primary Prevention,
Secondary Prevention
CTT 2010 (20)d26 trials
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23 In adults with CHD or acute coronary syndromes who received more
intensive compared with less intensive statin therapy, the RR for
coronary revascularization was reduced by approximately 34% per
1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Secondary Prevention CTT 2010 (20)d5 trials
24 In adults with and without CVD who received statin therapy compared with
placebo/control, the RR for coronary revascularization was reduced by
approximately 24% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Primary Prevention,
Secondary Prevention
CTT 2010 (20)d21 trials
25 In adults with and without CVD who received statin therapy, a larger
absolute reduction in LDL-C (mmol/L or mg/dL) was associated with a
greater reduction in the risk for CVD.
M Primary Prevention,
Secondary Prevention
CTT2010 (20), Kizer 2010 (136)
26 In adults with and without CVD who received statin therapy, there was no
variation in the relative reduction of CVD risk among the trials after
adjustment for LDL-C reduction. Thus, LDL-C reduction appeared to
account for the reduction in CVD risk.
M Primary Prevention,
Secondary Prevention
CTT 2010 (20)
27 Consistent 23%–28% relative reductions in CVD risk per 39-mg/dL
(1-mmol/L) reduction in LDL-C were observed after 1 year to beyond
5 years of statin treatment.
H Secondary Prevention,
Primary Prevention
CTT 2008 (134), 2005 (50) CTT 2010 (96)
28 Statins reduce the RR for CVD similarly in primary- and secondary-
prevention populations.
H Primary Prevention;
Secondary Prevention
CTT 2010 (20) CTT 2010 Web appendix (50)
29 In adults with diabetes (some of whom had CHD), statin therapy reduced
the RR for CVD events by approximately 20% per 1-mmol/L (38.7-mg/dL)
LDL-C reduction. This 1-mmol (20%) risk-reduction relationship was
similar for more intensive compared with less intensive statin therapy
and for statin therapy compared with placebo/control.
H Secondary Prevention
(includes diabetes
subgroup)
Primary Prevention in
Individuals With
Diabetes
CTT 2010 (20) CTT 2008 (134)
30 Adults with type 2, type 1, and no diabetes had similar RRRs in CVD per
1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Primary Prevention in
Individuals With
Diabetes
CTT 2010 (20)
31 In adults with diabetes without CVD, moderate-dose statin therapy,
compared with placebo/control, reduced the RR for CVD events by
approximately 27% per 1-mmol/L (38.7-mg/dL) LDL-C reduction.
H Primary Prevention in
Individuals With
Diabetes
CTT 2008 (134)d14 trials
32 In adults with diabetes, statin therapy reduced the RR for CVD by a similar
magnitude for subgroups of diabetic men and women, <65 and 65
years of age; treated hypertension; body mass index <25, >25 to <30,
and 30; systolic blood pressure <160 and 160 mm Hg; diastolic
blood pressure <90 and 90 mm Hg; current smokers and
nonsmokers; estimated GFR <60, 60 to <90, and 90 mL/min/
1.73 m2; and predicted annual risk for CVD <4.5%, >4.5% to <8.0%,
and 8.0%. Whereas RRRs are similar across these subgroups,
absolute risk reductions may differ for various subgroups.
H Primary Prevention in
Individuals With
Diabetes
CTT 2008 (134)d14 trials
33 In adults 40 to 75 years of age with diabetes and 1 risk factor, ﬁxed
moderate-dose statin therapy that achieved a mean LDL-C of 72 mg/dL
reduced the RR for CVD by 37% (in this trial, LDL-C was reduced by
46 mg/dL or 39%).
M Primary Prevention in
Individuals With
Diabetes
CARDS (75)
34 In men and postmenopausal women 40 to 73 years of age without CHD/
CVD, the majority of whom did not have diabetes and had baseline LDL-
C levels <190 mg/dL, ﬁxed low- to moderate-dose statin therapy that
achieved a mean LDL-C of 115–127 mg/dL reduced the RR for CVD by
24%–25%, compared with placebo, with mean LDL-C levels of 153–
156 mg/dL. (In these trials, LDL-C was reduced by 29–35 mg/dL and
19%–25% from baseline with a low- to moderate-dose statin.)
H Primary Prevention AFCAPS (17); MEGA (18)
35 In men 50 years and women 60 years of age without CHD/CVD with
LDL <130 mg/dL and hs-CRP 2 mg/L, ﬁxed intensive-dose statin that
achieved a mean LDL-C of 53 mg/dL reduced the RR for CVD events by
44% compared with placebo, which had a mean LDL-C 110 mg/dL. In
this trial, LDL-C was reduced by 53 mg/dL, or 49%.
M Primary Prevention JUPITER (49)
36 In adults without CVD (some of whom had diabetes) who received more
intensive or less intensive statin therapy, or statin therapy compared
with placebo/control, the RR for CVD events was reduced by
approximately 25% per 1-mmol/L LDL-C reduction. This was similar to
the CVD RRR observed in those with CHD or CVD.
H Primary Prevention CTT 2010 (20)
37 Statin therapy reduces CHD and stroke events in adults 40 years of age
without CHD/CVD, and with a wide range of baseline LDL-C levels.
H Primary Prevention CTT 2010 (20)
JUPITER (49)
AFCAPS (17)
MEGA (18)
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38 Statin therapy, with a range of LDL-C lowering, reduces all-cause mortality,
compared with placebo, in primary-prevention clinical trials of adults
who were in general 40 years of age and had at least 1 risk factor,
and with a wide range of baseline LDL-C levels.
M Primary Prevention CTT 2010 (20)
39 There is insufﬁcient evidence to determine the beneﬁt of statins in primary
prevention on all-cause mortality separately for women and men or with
advancing age.
I Primary Prevention CTT 2010 (20)
40 In MEGA (18), AFCAPS (17), JUPITER (49), and CARDS (75), the 10-year
NNTs to prevent 1 hard CVD event were 82, 56, 30, and 15,
respectively. These reﬂect RRRs of 24%, 26%, 44%, and 37%,
respectively, and placebo event rates for major CVD calculated at 10
years of 5.1%, 6.9%, 7.6%, and 18%, respectively.
M Primary Prevention CTT 2010 (20) appendix individual trialsdprojected
calculation
41 In adults without CVD (some of whom had diabetes) overall, who received
statin therapy compared with placebo/control, the RR for CVD events
was reduced by approximately 25% per 1-mmol/L LDL-C reduction. This
was similar to the CVD RRR observed in those with CHD or CVD.
H Primary Prevention,
Primary Prevention in
Individuals With
Diabetes
CTT 2010 (20)
42 Statin therapy, with a range of LDL-C lowering, reduces all-cause mortality
by about 10%, compared with placebo, in primary-prevention clinical
trials of adults who were 40 years of age and in general who had at
least 1 risk factor, and with a wide range of baseline LDL-C levels.
M Primary Prevention,
efﬁcacy
Cochrane (15), Ray (137), Brugts (138),
Bukkapatnam (139), JUPITER (49)
MEGAdwomen (140)
43 In adults with and without CVD, intensive- and moderate-dose statins do
not increase the risk for death from noncardiovascular causes,
regardless of baseline LDL-C. Statins do not increase (or decrease) the
risk for incident cancer overall or cancer of any type, or the risk for
cancer death.
H Primary Prevention,
Secondary Prevention,
Safety of Statins
CTT 2010 (20), Mills 2008 (97), Cochrane (15),
Bonovas (141)
44 In adults with or without CVD, statin therapy is associated with an excess
risk for incident diabetes.
 Statin therapy was associated with 1 excess case of incident
diabetes per 1,000 individuals treated for 1 year, compared with
placebo/control, with little heterogeneity among 13 trials (including
JUPITER [49]). Risk for diabetes was highest in older persons
(NNH¼1,002 per year).
 Statin therapy resulted in 5.4 fewer major CVD events per 1-mmol/L
LDL-C reduction per 1,000 individuals treated for 1 year compared
with placebo (NNT to beneﬁt, 185 per year).
 High-intensity statin therapy was associated with 2 excess cases of
incident diabetes per 1,000 individuals treated for 1 year, compared
with moderate-intensity statins (NNH¼498 per year). High-intensity
statin therapy resulted in 6.5 fewer major CVD events per 1,000
individuals treated for 1 year, compared with moderate-intensity
statin therapy (NNT¼155 per year). Rosuvastatin 20 mg was
associated with 3 excess cases of incident diabetes per 1,000
individuals treated for 1 year, compared with placebo (NNH¼332 per
year).
 Rosuvastatin 20 mg resulted in 5.9 fewer major CVD events per
1,000 individuals treated for 1 year, compared with placebo
(NNT¼169 per year).
M Primary Prevention,
Secondary Prevention,
Safety of Statins
Sattar 2010 (81)
Preiss (142), PROVE-IT (48), A–Z (117),
TNT (46), IDEAL (47), SEARCH (124),
JUPITER (49)
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45 In trials of high-intensity compared with moderate-intensity statins (clinical
CVD), moderate-intensity statin compared with placebo
(diabetesdprimary prevention), high-intensity statin compared with
placebo (secondary and primary prevention), or statin-niacin versus
placebo, participants were:
 Seen at visits that occurred at 4–13 weeks after randomization, and
every 3–6 months thereafter.
 Counseled on diet (IDEAL [47], AFCAPS [17], MEGA [18], PROVE-IT
[48], SPARCL [107]) and lifestyle (JUPITER [49]) at baseline and
regularly thereafter or when LDL-C increased (JUPITER [49], CARDS
[75]).
 Assessed for adherence to study medication at every visit.
 Assessed for adverse effects by history and laboratory
measurements at every visit or every other visit.
 Able to reduce the statin dose for adverse events so that atorvastatin
80 mg could be reduced to 40 mg (IDEAL [47], PROVE-IT [48]) or
pravastatin 40 mg could be reduced to 20 mg (PROVE-IT [48]) or
simvastatin reduced by 10 mg/d (HATS [121]).
 Able to reduce the statin dose if LDL-C decreased to <39 mg/dL
(1.0 mmol/L) (per investigator discretion in IDEAL [47]) or reduce
the statin dose if total cholesterol was <100 mg/dL on 2
successive visits (AFCAPS [17]) or reduce by 10 mg simvastatin
per day if LDL-C was <40 mg/d (HATS [121]), although they
continued on study drug no matter how low the cholesterol in
CARDS (75).
 Allowed to have their statin doses uptitrated or switched to more
potent statin to further reduce
 LDL-C (IDEAL [47], CARDS [75], AFCAPS [17], MEGA [18], PROVE-IT
[48]dpravastatin to 80 mg) if LDL-C exceeded 125 mg/dL.
 Given counseling on diet and/or glycemic control when LDL-C or
triglyceride levels increased (CARDS [75]).
 Had study medication discontinued for CK 10  ULN with muscle
aches or weakness, or persistent ALT 3  ULN on 2 consecutive
tests (JUPITER [49], CARDS [75]); the dose of atorvastatin or
pravastatin could be halved for abnormal LFTs, CK elevations, or
myalgias (PROVE-IT [48]).
H Statin Adherence Reﬂects review of TNT (46), IDEAL (47), PROVE-IT
(48), CARDS (75), JUPITER (49), SPARCL (107),
MEGA (18), AFCAPS (17) baseline and main
papers; these were statin trials that
demonstrated signiﬁcant CVD risk reduction (and
were the basis of recommendations arising from
CQ1 and CQ2) HATS (121)
46 Most RCTs of moderate-intensity statin therapy and all RCTs of high-
intensity statin therapy excluded subjects with serious comorbidities
and other conditions or concomitant drug therapy predisposing to
adverse events from statin therapy (see Table 9).
H Primary Prevention,
Secondary Prevention,
Safety of Statins,
Safety of Nonstatins
RCTs included in CQ1, 2, and 3:
A–Z (117), ACCORD (14), AIM-HIGH (9), ASPEN
(119), CARE (130), CDP (101), FIELD (115),
GREACE (120), HATS (121), HHS (111), HPS
(16), IDEAL (47), JUPITER (49), LIPID (74), LIPS
(122), LRC (113), MIRACL (93), MUSHASHI-AMI
(123), PROVE-IT (48), SEAS (108), SHARP (109),
SPARCL (107), TNT (46)
47 In adults with and without CVD who received more intensive compared
with less intensive statin therapy, or statin therapy compared with
placebo/control, overall the RR for ﬁrst hemorrhagic stroke was not
increased. Hemorrhagic stroke comprised 11% of total strokes in the
more intensive/statin group, compared with 8% in the less intensive/
control groups.
M Primary Prevention,
Secondary Prevention,
Safety of Statins
CTT 2010 (20)
48 In adults with and without CVD, statin-treated individuals in clinical trials
are not more likely to discontinue treatment than placebo-treated
individuals.
H Primary Prevention,
Secondary Prevention,
Safety of Statins
Cochraned14 trials (15), CTT 2010 (20)
49 In adults with and without CVD in clinical trials, low- to moderate-dose
statins do not increase the risk for myalgias or muscle pain.
H Primary Prevention,
Secondary Prevention,
Safety of Statins
Cochraned14 trials (15), CTT 2010 (20)
50 In adults selected for participation in clinical trials of statin therapy,
rhabdomyolysis occurred rarely (<0.06% over a mean 4.8- to 5.1-year
treatment period).
H Primary Prevention,
Secondary Prevention,
Safety of Statins
CTT 2010 (20)
51 In adults with CHD, the rate of creatine kinase elevation 3 times ULN
occurs infrequently and at a similar rate in those treated with intensive-
or moderate-dose statin therapy.
H Primary Prevention,
Secondary Prevention,
Safety of Statins
Dale (98), CTT 2010 (20)
52 In adults with CHD, although uncommon (<1.5% over 5 years), intensive
statin therapy increases the risk for elevated hepatic transaminase (ALT
and/or AST) levels 2–3 times ULN more than moderate-dose statin
therapy. No cases of hepatic failure were reported.
H Primary Prevention,
Safety of Statins
Dale (98), Cochrane (15), CTT 2010 (20), TNT (46),
IDEAL (47), PROVE-IT (48), JUPITER (49)
53 Low- to moderate-dose statin therapy has similar rates of elevated hepatic
transaminase levels as placebo/no statin treatment. In general, clinical
trials tend to underestimate those likely to have side effects, often
related to selection procedures.
H Primary Prevention,
Safety of Statins
CTT 2010 (20)
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54 With the exception of simvastatin 80 mg, intensive- and moderate-dose
statins did not increase the risk for rhabdomyolysis.
L Safety of Statins CTT 2010 (20), Cochrane (15), Mills (97)
55 In adults with CHD, CK elevation 3 times ULN occurs infrequently
and at a similar rate in those treated with intensive- or moderate-dose
statin therapy (0.02% [moderate-dose statin] to 0.1% [higher-dose
statin]) over a 1- to 5-year treatment period (RR 2.63, 95% CI
0.88–7.85).
H Secondary Prevention,
Safety
Dale 2007 (98)
56 The Expert Panel did not ﬁnd evidence that statins had an adverse effect
on cognitive changes or risk of dementia.
I Safety of Statins Reviewed RCTs in CQ1, CQ2; assessment of
cognitive function only reported in HPS (16)
57 In men with CHD who are 30 to 64 years of age, immediate-release
niacin (with an approximately 2-g dose):
 Decreased total cholesterol by 10% and triglycerides by 27%.
 Markedly increased the risk for adverse skin events (including
ﬂushing, pruritus, acanthosis nigricans, and other types of skin rash).
 Increased the risk for other adverse events:
 Atrial ﬁbrillation
 Gastrointestinal events (including nausea, stomach pain,
decreased appetite, and unexplained weight loss)
 Gout
 Elevated levels of uric acid, serum glutamic oxaloacetic
transaminase, alkaline phosphatase, and glucose
 Lipids, LFTs, uric acid, and glucose were monitored during up-titration
and every 4–12 months thereafter.
L Secondary Prevention,
Safety,
Monotherapy,
Safety,
Efﬁcacy
CDP (101,143)
58 In a trial in 67 adults with CHD and low HDL-C, slow-release niacin (at a
mean 2.4-g dose) plus low-dose simvastatin resulted in the following:
 Low levels of LDL-C and raised levels of HDL-C.
 Although not powered to detect a reduction in CVD events, the rate of
major clinical events was 90% lower than that in the placebo group.
 Slow-release niacin did not cause ﬂushing in this trial.
 The simvastatin-niacin group had increased ALT, CK, uric acid,
and homocysteine.
 Antioxidant vitamins diminished the beneﬁcial effect of niacin
on HDL-C.
 Lipids, LFTs, uric acid, and glucose were monitored during up-titration
and every 2–4 months thereafter.
L Secondary Prevention,
Combination Treatment
HATS Investigators (121)
59 In adults 45 years of age and older with established CVD and low HDL-C
(<40 mg/dL in men or <50 mg/dL in women), elevated triglycerides
(150–400 mg/dL), and LDL-C <180 mg/dL off statin, in whom the
dose of simvastatin was adjusted, or ezetimibe was added, to maintain
LDL-C in a range of 40–80 mg/dL, extended-release niacin 1,500–
2,000 mg/day plus simvastatin (9.5% also on ezetimibe 10 mg)
compared with placebo (with 50 mg immediate-release niacin) plus
simvastatin (21.5% also on ezetimibe 10 mg:
 Improved the lipid proﬁle without a further decrease in CVD events.
Speciﬁcally, it lowered LDL-C levels an additional 6%, increased HDL-
C by an additional 14%, reduced triglycerides by an additional 23%,
lowered apolipoprotein B by an additional 10%, and reduced
lipoprotein(a) by an additional 19%.
 There were similar rates of CVD events in subgroups by age, sex, or
diabetes, metabolic syndrome, or previous myocardial infarction
status, as well as similar rates of adverse events, including liver
function abnormalities, muscle symptoms, and rhabdomyolysis.
 Lipids, LFTs, uric acid, and glucose were monitored during up-titration
and every 3–12 months thereafter.
M Secondary Prevention,
Combination Treatment
AIM-HIGH Investigators (9)
60 In men 35–59 years of age without CHD, hypertension, diabetes, or obesity
and with LDL-C 175 mg/dL and triglycerides <300 mg/dL,
cholestyramine:
 Reduced LDL-C by 13%, with minimal changes in triglycerides or
HDL-C levels.
 Reduced the RR for CHD events by 19%.
 Increased the risk for adverse gastrointestinal effects, including
constipation, heartburn, abdominal pain, belching, bloating, gas,
nausea.
 Adherence was only modest.
L Primary Prevention,
Safety,
Efﬁcacy
LRC (113)
61 Insufﬁcient data to evaluate the efﬁcacy and safety of ezetimibe
monotherapy.
I Efﬁcacy,
Safety,
Nonstatin
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62 Insufﬁcient data to evaluate the additional efﬁcacy and safety of ezetimibe
in combination with a statin compared with a statin alone.
I Safety,
Efﬁcacy,
Combination Treatment
63 In adults 45–85 years of age with mild to moderate aortic stenosis and
without CVD or diabetes, simvastatin 40 mg coadministered with
ezetimibe 10 mg, compared with placebo:
 Decreased LDL-C by an average of 50%.
 Reduced the RR for CVD events by 22% over 4.35 years of treatment.
 Increased the risk for elevated hepatic transaminases.
L Safety,
Efﬁcacy,
Combination Treatment
SEAS (108)
64 In adults 40 years of age with CKD, of whom 33% were receiving dialysis
(peritoneal or hemodialysis), ezetimibe 10 mg coadministered with
simvastatin 20 mg, compared with placebo:
 Lowered LDL-C by 37 mg/dL (33%) in those who were not
receiving dialysis and by 23% in those who were receiving dialysis.
 Reduced the risk for CVD events by 17% overall and 21% in
those without CVD.
 Reduced the risk for CVD events by 22% in those who were
not receiving dialysis.
 Did not reduce CVD events in those with CVD or in those receiving
hemodialysis.
 Modestly increased the risk for muscle symptoms requiring
discontinuation of treatment (1.1% vs. 0.6% with p¼0.02).
 Did not increase the risk for elevated hepatic transaminases, cancer,
hemorrhagic stroke, or noncardiovascular mortality.
L Safety,
Efﬁcacy,
Combination Treatment,
CKD
SHARP (109)
65 Ezetimibe coadministered with simvastatin does not appear to increase
the risk for cancer compared with placebo.
L Safety,
Combination Treatment
SHARP (109)
66 In adults 50–75 years of age with diabetesdwith total cholesterol <250
mg/dL, and total cholesterol/HDL ratio 4.0 or triglycerides <450
mg/dLdfenoﬁbrate, compared with placebo:
 Modestly reduced LDL-C, minimally increased HDL-C, and
substantially reduced triglycerides.
 In those without clinical CVD, reduced the risk for CHD/CVD events.
 In those with clinical CVD, did not reduce the risk for
CHD/CVD events.
 Was no different than placebo for myositis or rhabdomyolysis, CK or
ALT elevations, renal disease requiring hemodialysis, or cancer.
 Was associated with higher rates of pancreatitis and pulmonary
embolism, and increased creatinine levels on average by
0.113–0.136 mg/dL (10–12 mmol/L).
L Safety,
Efﬁcacy,
Nonstatin Treatment
FIELD (115)
67 In adults 40–79 years of age with diabetes, CVD, and/or CVD risk factors,
with LDL-C 60–180 mg/dL, HDL-C <55 mg/dL in women and black
individuals, HDL-C <50 mg/dL for all others, and triglycerides
<750 mg/dL on no medication or <400 mg/dL on medication:
 Fenoﬁbrate added to simvastatin did not additionally reduce LDL-C,
minimally increased HDL-C (1 mg/dL or 2%), and moderately
reduced triglycerides (23 mg/dL or 14%), compared with simvastatin
therapy, which had on-treatment mean LDL-C of 80 mg/dL, HDL-C of
40.5 mg/dL, and triglycerides of 170 mg/dL.
 In the trial overall, and in those without and with clinical CVD,
fenoﬁbrate-simvastatin did not reduce the risk for CVD events
compared with simvastatin alone.
 Those with triglycerides 204 mg/dL and HDL-C 40 mg/dL may
have experienced a reduction in CVD events from fenoﬁbrate-
simvastatin, compared with simvastatin alone.
 Fenoﬁbrate-simvastatin had similar rates as simvastatin alone for
myopathy, myositis, or rhabdomyolysis; CK or ALT elevations,
renal disease requiring hemodialysis; cancer death; or pulmonary
embolism/thrombosis.
 Fenoﬁbrate-simvastatin was more likely to increase ALT >5 times
ULN and to increase creatinine level.
 CVD event rates were higher in women with well-controlled diabetes
who received fenoﬁbrate-simvastatin compared with simvastatin alone.
M Safety,
Efﬁcacy,
Nonstatin Treatment
ACCORD (14)
68 Inmen40–55 years of agewithout CHD or CHF and non–HDL-C200mg/dL,
gemﬁbrozil:
 Reduced LDL-C by 10% and triglycerides by 43%, and increased
HDL-C by 10%.
 Reduced the RR for CHD by 37%, compared with placebo.
 Increased skin cancer, increased gastrointestinal surgery, and
increased severe upper gastrointestinal symptoms, especially in ﬁrst
year. There was no difference in diarrhea, constipation, nausea, or
vomiting. Total mortality was not reported.
M Safety,
Efﬁcacy,
Nonstatin Treatment
Helsinki Heart Study (111)
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Appendix 4. Continued
ES No. Evidence Statement
Level of
Evidence
Recommendation(s)/
Section References
69 In men with CHD who were <74 years of age with HDL-C 40 mg/dL and
LDL-C 140 mg/dL, and triglycerides 300 mg/dL, gemﬁbrozil,
compared with placebo:
 Did not reduce LDL-C, but did reduce triglycerides by 31% and
increase HDL-C by 6%.
 Reduced the RR for CVD by 24%.
M Efﬁcacy,
Nonstatin Treatment
VA-HIT (114)
70 In Japanese men who were 40–75 years of age and postmenopausal
women75 years of age with and without CHD and LDL-C170 mg/dL,
EPA 1,800 mg added to statin therapy:
 Did not reduce LDL-C and modestly reduced triglycerides (5%),
compared with statin therapy alone.
 Reduced the risk for CHD events (including revascularization and
unstable angina) by 19%, compared with statin therapy alone.
 Caused a similar magnitude of risk reduction in primary- and
secondary-prevention populations, but the study was insufﬁciently
powered to evaluate these populations separately.
 Increased the risk for gastrointestinal disturbance, skin abnormal-
ities, hemorrhage, and abnormal serum glutamic oxaloacetic
transaminase.
M Efﬁcacy,
Safety,
Combination Treatment
JELIS (110)
71 In individuals with NYHA Classes II–IV systolic or ischemic heart failure,
initiation of a statin did not change the absolute or RR for CVD
compared with placebo.
M Efﬁcacy,
Selected Population
Subgroups
CORONA (85) from CQ1
72 In individuals receiving maintenance hemodialysis, initiation of a statin did
not change the relative or absolute risk for CVD compared with placebo.
M Efﬁcacy,
Selected Population
Subgroups
4D (87) and AURORA (84) CQ1 & CQ2,
SHARP (109)dHD subgroup
73 In men and women of mean age 58 to 68 years with aortic stenosis,
treatment with statin or statin plus ezetimibe for a mean of 2.1–4.4
years resulted in a reduction in LDL-C of 50%–55% (67–73 mg/dL)
from a baseline LDL-C of 123–140 mg/dL and did not alter the
progression of aortic stenosis as assessed by change in valve area,
peak aortic valve jet velocity, peak or mean aortic valve gradient,
or need for aortic valve surgery.
H Aortic Stenosis,
Combination Treatment
Parolari (144)
74 Women who were pregnant or nursing were excluded from statin,
fenoﬁbrate, niacin-statin, and ezetimibe-statin RCTs.
Only men were enrolled in RCTs of niacin, BAS, and gemﬁbrozil.
H Primary Prevention,
Secondary Prevention
All RCTs CQ1, CQ2, and CQ3
75 Only individuals with primary hypercholesterolemia were included in RCTs. H Primary Prevention,
Secondary Prevention
AFCAPS (17)
JUPITER (49)
JELIS (110)
HATS (121)
FIELD (115)
ACCORD (14)
MEGA (18)
76 In the 3 exclusively primary-prevention RCTs, low-, moderate-, and high-
intensity statin therapy reduced the risk for ASCVD when LDL-C levels
were approximately 70–130 mg/dL, 130–190 mg/dL, and 160–200
mg/dL.
H Primary Prevention JUPITER (49)
MEGA (18)
AFCAPS (17)
77 Lipids, liver function, uric acid, and glucose tests were obtained at
baseline, during up-titration, and every 2–12 months thereafter.
H Secondary Prevention CDP (101) (fair) 4–12 months;
HATS (121) (good) 2–4 months;
AIM-HIGH (9) (good) 3–12 months
78 Immediate- and extended-release niacin increase cutaneous adverse
effects.
M Secondary Prevention CDP (101), AIM-HIGH (9) (not HATS [121]d
Slo-Niacin)
79 When used as monotherapy or with a statin, niacin increases:
 Hepatic function tests.
 Hyperglycemia.
 Gastrointestinal adverse effects.
 Gout or increased uric acid.
H
M
M
M
Secondary Prevention,
Safety
(CDP [101], HATS [121], AIM-HIGH [9])
(CDP [101], AIM-HIGH [9]dniacin dose reduced or
discontinued)
(CDP [101], AIM-HIGH [9]dniacin dose reduced or
discontinued)
Gout (CDP [101])
Increased uric acid (HATS [121])
80 Niacin increases the incidence of atrial ﬁbrillation and weight loss. L Secondary Prevention,
Safety
CDP (101) (atrial ﬁbrillation not reported in
AIM-HIGH [9] or HATS [121])
ALT indicates alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; BAS, bile acid sequestrant; BID, twice daily; CHD, coronary heart disease; CHF, congestive heart failure; CK, creatine
kinase; CKD, chronic kidney disease; CVD, cardiovascular disease; EPA, eicosapentaenoic acid; GFR, glomerular ﬁltration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; LFT, liver function test; MI, myocardial infarction; NNH, number needed to harm; NNT, number needed to treat; NYHA, New York Heart Association; RCT, randomized controlled trial; RR,
relative risk; RRR, relative risk reduction; TIA, transient ischemic attack; and ULN, upper limit of normal.
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2932Appendix 5. Expanded Discussion of What’s New in the GuidelineFocus on ASCVD Risk Reduction: 4 Statin Beneﬁt Groups
 The 2013 guideline focuses on treatment of blood cholesterol to reduce ASCVD risk. Each Expert Panel was limited in the number of CQs it could choose. When
the CQs from the Risk Assessment and Lifestyle Work Groups were combined with the 3 Cholesterol Panel CQs, there were 8 CQs in total that were systematically
reviewed. All 3 CQs of the Cholesterol Panel evaluated evidence from RCTs with ASCVD outcomes. CQ1 and CQ2 evaluated the evidence for LDL-C and non–HDL-C
goals in secondary and primary prevention. CQ3 was a comprehensive evaluation of the reduction in ASCVD events and safety for each of the cholesterol-lowering
drugs available in the United States.
 The systematic review of evidence from the highest-quality RCTs with ASCVD outcomes identiﬁed strong evidence to indicate who should get which therapy at what
intensity.
 The statin RCTs provided the most extensive evidence for the greatest magnitude of ASCVD event reduction, with the best margin of safety.
 Four statin beneﬁt groups were identiﬁed, in which the potential for an ASCVD risk-reduction beneﬁt clearly exceeds the potential for adverse effects in:
1. Individuals with clinical ASCVD
2. Individuals with primary elevations of LDL-C 190 mg/dL
3. Individuals 40–75 years of age with diabetes but without clinical ASCVD and LDL-C 70–189 mg/dL
4. Individuals 40–75 years of age without diabetes or clinical ASCVD with LDL-C 70–189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher.
This requires a clinician-patient discussion.
 Because few trials have been performed with nonstatin cholesterol-lowering drugs in the statin era, and those that have been performed were unable to
demonstrate signiﬁcant additional ASCVD event reductions in the RCT populations studied, there was less evidence to support the use of nonstatin drugs for
ASCVD prevention.
 It is difﬁcult to determine how observational data could override the conclusions from the extensive body of evidence from the statin RCTs and the paucity of
evidence from nonstatin RCTs. Inherent biases of observational data are well understood and include biases in the decisions on whom to treat and who is adherent
to therapy, as well as multiple measurement biases, including veriﬁcation of statin use, type and dose of statin used, consistency of use over time, and outcome
ascertainment. All of these problems are addressed in intent-to-treat analyses of RCTs, which is why the FDA requires well-designed RCTs to determine drug efﬁcacy
for ASCVD event reduction and common adverse effects.
 Other approaches to treatment of blood cholesterol have been advocated, including:
A. Treat to targetdThis strategy has been the most widely used in the past 15 years, but there are 3 problems with this approach. First, current clinical trial data do
not indicate what the target should be. Second, we do not know the magnitude of additional ASCVD risk reduction that would be achieved with one target lower
than another. Third, this strategy does not take into account potential adverse effects from statin monotherapy or from multidrug therapy that might be needed
to achieve a speciﬁc goal. Thus, in the absence of these data, this approach is less useful than it appears (Section 3). It is possible that future clinical trials may
provide information warranting reconsideration of this strategy.
B. Lowest is bestdThis approach was not taken because it does not consider the potential adverse effects of multidrug therapy with an unknown magnitude of
ASCVD event reduction. Ongoing RCTs of new LDL-C–lowering drugs in the setting of maximal statin therapy may address this question.
C. Treat level of ASCVD riskdA modiﬁed version of this approach was taken, which considers both the ASCVD risk-reduction beneﬁts and the adverse effects of
statin treatment on the basis of an extensive body of RCT evidence to determine the 4 statin beneﬁt groups. By focusing treatment on the 4 statin beneﬁt groups,
the approach is practical and simpler to implement than the past strategies. There are also important exceptions for routine initiation of statin treatment for
individuals requiring hemodialysis or with NYHA class II to IV heart failure.
D. Lifetime riskdTreatment strategies based on lifetime ASCVD risk are problematic because of the lack of data on the long-term follow-up of RCTs >15 years, the
safety and ASCVD event reduction when statins are used for periods >10 years, and treatment of individuals <40 years of age.
A New Perspective on LDL-C and/or Non–HDL-C Goals
 The difﬁculty of giving up the treat-to-goal paradigm was deliberated extensively over a 3-year period. Many clinicians use targets such as LDL-C <70 mg/dL and
LDL-C <100 mg/dL for secondary and primary ASCVD prevention (non–HDL-C targets are 30 mg/dL higher). However, the RCT evidence clearly shows that ASCVD
events are reduced by using the maximum-tolerated statin intensity in those groups shown to beneﬁt. After a comprehensive review, no RCTs were identiﬁed that
titrated drug therapy to speciﬁc LDL-C or non–HDL-C goals to improve ASCVD outcomes. However, one RCT was identiﬁed that showed no additional ASCVD event
reduction from the addition of nonstatin therapy to further treat non–HDL-C levels once an LDL-C goal was reached. In AIM-HIGH (9), the additional reduction in non–
HDL-C levels [as well as additional reductions in Apo B, Lp(a), and triglycerides in addition to HDL-C increases] with niacin therapy DID NOT further reduce ASCVD risk
in individuals treated to LDL-C levels of 40–80 mg/dL.
 Use of LDL-C targets may result in under treatment with evidence-based statin therapy or overtreatment with nonstatin drugs that have not been shown to reduce
ASCVD events in RCTs (even though the drug may additionally lower LDL-C and/or non–HDL-C). Implications of treating to an LDL-C goal may mean that a
suboptimal intensity of statin is used because the goal has been achieved, or that adding a nonstatin therapy to achieve a speciﬁc target results in down-titration of
the evidence-based intensity of statin for safety reasons. However, when RCT evidence is available that a nonstatin therapy further reduces ASCVD events when
added to statin therapy, the nonstatin therapy may be considered.
 Some examples comparing a strategy based on the 4 statin beneﬁt groups to a strategy using LDL-C/non–HDL-C targets:
A. Secondary preventiondEvidence supports high-intensity statin therapy for this group to maximally lower LDL-C. It does not support the use of an LDL-C target.
For example, if a secondary-prevention patient achieves an LDL-C of 78 mg/dL on a dose of 80 mg of atorvastatin, he/she is receiving evidence-based therapy.
As of yet, there are no data to show that adding nonstatin drug(s) to high-intensity statin therapy will provide incremental ASCVD risk-reduction beneﬁt with an
acceptable margin of safety. Indeed, AIM-HIGH (9) demonstrated the futility of adding niacin in individuals with low HDL-C and high triglycerides, and ACCORD
(14) demonstrated the futility of adding fenoﬁbrate in persons with diabetes. Although an ACCORD subgroup analysis of those with high triglycerides and low
HDL-C levels suggested that fenoﬁbrate may reduce ASCVD events in patients with diabetes, this is hypothesis generating and needs further testing in
comparison to the evidence-based use of a high-intensity statin. In addition, not having a goal of <70 mg/dL for LDL-C means that the patient who is adhering to
optimal lifestyle management and receiving a high-intensity statin avoids additional, non–evidence-based therapy just because his/her LDL-C is higher than an
arbitrary cutpoint. Indeed, the LDL-C goal approach can make this patient unnecessarily feel like a failure.
Continued on the next page
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B. Familial hypercholesterolemia with LDL-C 190 mg/dLdIn many cases, individuals with familial hypercholesterolemia are unable to achieve an LDL-C
goal <100 mg/dL. For example, an individual with familial hypercholesterolemia may achieve an LDL-C of only 120 mg/dL despite use of 3 cholesterol-
lowering drugs. Although this patient may have fallen short of the 100-mg/dL goal, he/she has decreased his/her LDL-C by >50% (starting from an untreated
LDL-C level of w325–400 mg/dL). These patients are not treatment failures, as observational data has shown signiﬁcant reductions in ASCVD events without
achieving speciﬁc LDL-C targets. This is an area where observational data supports the recommended approach.
C. Type 2 diabetesdFor those 40–75 years of age with risk factors, the potential beneﬁts of LDL-C lowering with a high-intensity statin are substantial. Because
those with diabetes often have lower LDL-C levels than those without diabetes, “goal”-directed therapy often encourages use of a lower statin dose than is
supported by the RCTs, and nonstatin drugs may be added to address low HDL-C or high triglycerides, for which RCT evidence of an ASCVD event reduction is
lacking. Giving a maximally tolerated statin intensity should receive primary emphasis because it most accurately reﬂects the data that statins reduce the
relative risk of ASCVD events similarly in individuals with and without diabetes, and in primary and secondary prevention in those with diabetes, along with
evidence that high-intensity statins reduce ASCVD events more than moderate-intensity statins.
D. Estimated 10-year ASCVD risk ‡7.5%dData have shown that statins used for primary prevention have substantial ASCVD risk-reduction beneﬁts across the
range of LDL-C levels of 70–189 mg/dL. Moreover, the Cochrane meta-analysis (15), as well as a meta-analysis by the Cholesterol Treatment Trialists (13),
conﬁrms that primary prevention with statins reduces total mortality as well as nonfatal ASCVD events.
 RCTs are used to identify those who are unlikely to beneﬁt from initiation of statin therapy despite being at high ASCVD risk, such as those with higher NYHA classes
of heart failure or those on hemodialysis.
Global Risk Assessment for Primary Prevention
 Use of the new Pooled Cohort Equations is recommended to estimate 10-year ASCVD risk in both white and black men and women who do not have clinical ASCVD.
 By more accurately identifying higher-risk individuals for statin therapy, the guideline focuses statin therapy on those most likely to beneﬁt.
 It also indicates, on the basis of RCT data, those high-risk groups that might not beneﬁt. The Expert Panel emphasizes that the guideline is “patient centered” in
primary prevention. It is recommended that the potential for an ASCVD risk-reduction beneﬁts, adverse effects, and drug–drug interactions, along with patient
preferences, must be considered before statins are initiated for the primary prevention of ASCVD. Other factors such as LDL-C 160 mg/dL may also be considered.
This gives clinicians and patients the opportunity for input into treatment decisions rather than a simplistic “one-treatment-ﬁts-all” approach to drug therapy.
 These guidelines are not a replacement for clinical judgment; they are meant to guide and inform decision making.
 Some worry that a person 70 years of age without other risk factors will receive statin treatment on the basis of age alone. The estimated 10-year risk is still 7.5%,
a risk threshold for which a reduction in ASCVD risk events has been demonstrated in RCTs. Most ASCVD events occur after age 70 years, giving individuals 70
years of age the greatest potential for absolute risk reduction.
 Some have proposed using selected inclusion criteria from RCTs to determine the threshold for statin initiation. However, the Cholesterol Treatment Trialists
individual-level meta-analysis showed that statin therapy reduces ASCVD events regardless of categorical risk factors in both primary and secondary prevention.
Therefore, the rationale for using ﬁxed cutpoints to determine whether statin therapy should be initiated is refuted by a consideration of the total body of evidence
from RCTs.
 In addition, a trial-based strategy identiﬁes those at increased ASCVD risk less accurately than does a strategy based on an assessment of global ASCVD risk. This
selective use of inclusion criteria excludes well-established risk factors, such as smoking and advancing age (the strongest risk factor because it represents
cumulative risk factor exposure).
 The poor discrimination of RCT inclusion criteria for identifying those at increased 10-year ASCVD risk is shown by a calculation performed by the Risk Assessment
Work Group using nationally representative data from NHANES. Use of the RCT inclusion criteria (from RCTs that found a reduction in ASCVD events to guide
initiation of statin therapy) would result in the treatment of 16% of individuals with <2.5% estimated 10-year ASCVD risk and 45% of those with 2.5% to <5%
estimated 10-year ASCVD risk (many would say inappropriately), whereas 38% of those with 7.5% 10-year ASCVD risk would not have been identiﬁed as
candidates for statin therapy.
Safety
 RCTs are used to identify important safety considerations in individuals receiving treatment of blood cholesterol to reduce ASCVD risk and to determine statin
adverse effects to facilitate understanding of the net beneﬁt from statin therapy.
 Safety issues that are uncommon or unlikely to be seen in the populations studied in RCTs require more than analyses of single RCTs. This limitation was overcome,
in part, by considering high-quality systematic reviews and meta-analyses of statin RCTs.
 Expert guidance is provided on management of statin-associated adverse effects, including muscle symptoms.
 This guideline emphasizes the importance of using additional sources of information on safety, including FDA reports, manufacturers’ prescribing information, and
pharmacists, to aid in the safe use of cholesterol-lowering drug therapy.
Role of Biomarkers and Noninvasive Tests
 There is a concern about other factors that may indicate elevated ASCVD risk but were not included in the Pooled Cohort Equations for predicting 10-year ASCVD
risk.
 The Risk Assessment Work Group has performed an updated systematic review of nontraditional risk factors, such as CAC, and has included recommendations to
consider their use to the extent that the evidence allows.
 In selected individuals who are not in 1 of the 4 statin beneﬁt groups, and for whom a decision to initiate statin therapy is otherwise unclear, additional factors may
be considered to inform treatment decision making.
 These factors include primary LDL-C 160 mg/dL or other evidence of genetic hyperlipidemias; family history of premature ASCVD with onset <55 years of age in a
ﬁrst-degree male relative or <65 years of age in a ﬁrst-degree female relative; high-sensitivity C-reactive protein 2 mg/L; CAC score 300 Agatston units or 75th
percentile for age, sex, and ethnicity; ankle-brachial index <0.9; and elevated lifetime risk of ASCVD. Additional factors may be identiﬁed in the future.
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Appendix 5. Continued
Future Updates to the Blood Cholesterol Guideline
 This guideline focuses on treatments proven to reduce ASCVD events. It is not and was never intended to be a comprehensive approach to lipid management.
 Using RCT evidence assessed for quality provides a strong foundation for treatment of blood cholesterol to reduce ASCVD risk that can be used now. There are many
clinical questions for which there is an absence of RCT data available to develop high-quality, evidence-based recommendations. For these questions, expert opinion
may be helpful to clinicians and could be developed in the next iteration of the guideline.
 CQs for future guidelines could examine:
1. the treatment of hypertriglyceridemia;
2. the use of non–HDL-C in treatment decision making;
3. whether on-treatment markers such as Apo B, Lp(a), or LDL particles are useful for guiding treatment decisions;
4. the best approaches to using noninvasive imaging for reﬁning risk estimates to guide treatment decisions;
5. how lifetime ASCVD risk should be used to inform treatment decisions and the optimal age for initiating statin therapy to reduce lifetime risk of ASCVD;
6. subgroups of individuals with heart failure or undergoing hemodialysis who might beneﬁt from statin therapy;
7. long-term effects of statin-associated new-onset diabetes and management;
8. efﬁcacy and safety of statins in patient groups excluded from RCTs to date (e.g., those who are HIV positive or have received a solid organ transplant); and
9. role of pharmacogenetic testing.
*For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.
AIM-HIGH indicates Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes; ACCORD, Action to Control Cardiovascular Risk in
Diabetes; Apo B, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CQ, critical question; FDA, U.S. Food and Drug Administration; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); NHANES, National Health and Nutrition Examination Survey; and RCTs, randomized controlled trials.
Stone et al. JACC Vol. 63, No. 25, 2014
2013 ACC/AHA Blood Cholesterol Guideline July 1, 2014:2889–934
2934
